<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005982.pub2" GROUP_ID="PVD" ID="303105060622464006" MERGED_FROM="" MODIFIED="2014-03-10 10:49:31 +0000" MODIFIED_BY="Marlene Stewart" REVIEW_NO="1062" REVMAN_SUB_VERSION="5.2.9 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2014-03-10 10:49:31 +0000" MODIFIED_BY="Marlene Stewart">
<TITLE>Low molecular weight heparin for prevention of central venous catheterization-related thrombosis in children</TITLE>
<CONTACT MODIFIED="2014-03-10 10:49:31 +0000" MODIFIED_BY="Marlene Stewart"><PERSON ID="36775078769971951750100823134812" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Leonardo</FIRST_NAME><MIDDLE_INITIALS>R</MIDDLE_INITIALS><LAST_NAME>Brandão</LAST_NAME><POSITION>Assistant Professor</POSITION><EMAIL_1>leonardo.brandao@sickkids.ca</EMAIL_1><ADDRESS><DEPARTMENT>Division of Haematology-Oncology</DEPARTMENT><ORGANISATION>The Hospital for Sick Children</ORGANISATION><ADDRESS_1>555 University Avenue, Black Wing, room 10412</ADDRESS_1><CITY>Toronto</CITY><ZIP>M5G-1X8</ZIP><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>(416) 813 7758</PHONE_1><FAX_1>(416) 813 5327</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-03-10 10:49:31 +0000" MODIFIED_BY="Marlene Stewart"><PERSON ID="36775078769971951750100823134812" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Leonardo</FIRST_NAME><MIDDLE_INITIALS>R</MIDDLE_INITIALS><LAST_NAME>Brandão</LAST_NAME><POSITION>Assistant Professor</POSITION><EMAIL_1>leonardo.brandao@sickkids.ca</EMAIL_1><ADDRESS><DEPARTMENT>Division of Haematology-Oncology</DEPARTMENT><ORGANISATION>The Hospital for Sick Children</ORGANISATION><ADDRESS_1>555 University Avenue, Black Wing, room 10412</ADDRESS_1><CITY>Toronto</CITY><ZIP>M5G-1X8</ZIP><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>(416) 813 7758</PHONE_1><FAX_1>(416) 813 5327</FAX_1></ADDRESS></PERSON><PERSON ID="01C0970682E26AA200492FF15CC279A8" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Niketa</FIRST_NAME><LAST_NAME>Shah</LAST_NAME><POSITION>Pediatric Resident</POSITION><EMAIL_1>niketashah@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>New Jersey Hospital</ORGANISATION><ADDRESS_1>1104-30 Newport Parkway</ADDRESS_1><CITY>Jersey City</CITY><ZIP>07310</ZIP><REGION>New Jersey</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 551 580 5605</PHONE_1></ADDRESS></PERSON><PERSON ID="12333" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Prakeshkumar</FIRST_NAME><MIDDLE_INITIALS>S</MIDDLE_INITIALS><LAST_NAME>Shah</LAST_NAME><SUFFIX>MSc, MBBS, MD, DCH, MRCP, FRCPC</SUFFIX><POSITION>Neonatologist and Clinical Epidemiologist Associate Professor</POSITION><EMAIL_1>pshah@mtsinai.on.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatrics and Health Policy, Management and Evaluation</DEPARTMENT><ORGANISATION>University of Toronto Mount Sinai Hospital</ORGANISATION><ADDRESS_1>600 University Avenue</ADDRESS_1><CITY>Toronto</CITY><ZIP>M5G 1XB</ZIP><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 416 586 4761</PHONE_1><PHONE_2>+1 416 334 6661</PHONE_2><FAX_1>+1 416 586 8745</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-08-05 09:01:13 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="11" MONTH="6" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="11" MONTH="6" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="11" MONTH="6" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2014"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2013-05-30 08:58:38 +0100" MODIFIED_BY="[Empty name]"/>
<HISTORY MODIFIED="2013-05-30 08:58:38 +0100" MODIFIED_BY="Marlene Stewart">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-05-30 08:58:38 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="5" YEAR="2013"/>
<DESCRIPTION>
<P>Link to anticoagulant feedback added</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-02-14 11:57:36 +0000" MODIFIED_BY="Marlene Stewart">
<DATE DAY="30" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2014-03-10 10:14:37 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2011-09-01 09:36:11 +0100" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>The Department of Pediatrics, Mount Sinai Hospital, Toronto</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2011-09-01 09:36:11 +0100" MODIFIED_BY="[Empty name]">
<NAME>Department of Hematology and Oncology, Haemostasis and Thrombosis Program, The Hospital For Sick Children, Toronto</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2014-03-10 10:14:37 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2014-03-10 10:14:37 +0000" MODIFIED_BY="[Empty name]">
<NAME>Chief Scientist Office, Scottish Government Health Directorates, The Scottish Government</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The PVD Group editorial base is supported by the Chief Scientist Office</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-03-10 10:13:28 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2014-03-07 08:33:10 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2014-03-07 08:33:00 +0000" MODIFIED_BY="[Empty name]">Blood thinners for the prevention of blood clots in children with central venous lines</TITLE>
<SUMMARY_BODY MODIFIED="2014-03-07 08:33:10 +0000" MODIFIED_BY="[Empty name]">
<P>Over the last 10 years, the number of children found to have blood clots in their blood vessels, called veins, has become more common. As blood clots can either block these vessels and change their normal blood flow or shower pieces into other veins placed in important organs, serious health problems including death can occur. Venous clots are usually found in children with plastic tubes placed inside their blood vessels, called central lines, which are inserted to help or save the patient's life. However, these lines can also cause blood clots. We do not know if giving a medication to protect against blood clots, called an anticoagulant or low molecular weight heparin (LMWH), would protect against the clots. Therefore, we looked at all the research in children with central lines who received, or not, LMWH and only found one study with a total of 186 participants. This study did not have enough participants to show if this medication protects children with central lines from getting blood clots. The study also did not show that children on LMWH, at the doses given, experience too much bleeding because of its use. The included study did not report any additional adverse events. There were two deaths within the study in the standard care arm, and neither were due to a blood clot. Future studies looking at the role of this medication (LMWH) and if it protects children with central venous lines from getting blood clots are needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-03-07 08:33:00 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2014-03-07 00:37:59 +0000" MODIFIED_BY="[Empty name]">
<P>The prevalence of children diagnosed with deep vein thrombosis or pulmonary embolism has been increasing in the last decade. The most common thrombosis risk factor in neonates, infants and children is the placement of a central venous catheter (CVC). To date, it is unknown if the practice of anticoagulation prophylaxis with low molecular weight heparin (LMWH) decreases CVC-related thrombosis in children.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-03-07 00:36:39 +0000" MODIFIED_BY="[Empty name]">
<P>The primary objective of this review was to determine the effect of LMWH prophylaxis on reducing the incidence of CVC-related thrombosis in children.</P>
<P>Secondary objectives were to determine the effect of LMWH on occlusion of CVCs, number of days of CVC patency, episodes of catheter-related sepsis, side effects of LMWH (allergic reactions, major and minor bleeding complications, abnormal coagulation profile, osteoporosis) and mortality during therapy.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-08-02 09:41:22 +0100" MODIFIED_BY="[Empty name]">
<P>The Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched June 2013), CENTRAL (2013, Issue 5) and clinical trial databases. The authors searched MEDLINE and EMBASE (July 2013). Bibliographies of identified articles were searched. There were no language restrictions. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-03-07 08:33:00 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised and quasi-randomised trials comparing LMWH prophylaxis to standard care given to prevent CVC-related thrombotic events in children were included. We selected studies conducted in children aged 0 to 18 years.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-03-07 00:40:52 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently identified eligible studies, which were assessed for study quality including bias, and extracted unadjusted data where available. In the data analysis step, all outcomes were analysed as binary or dichotomous outcomes. The effects of interventions were summarised with risk ratios (RR) and their respective 95% confidence intervals (CI).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-03-07 00:51:20 +0000" MODIFIED_BY="[Empty name]">
<P>One of 17 studies retrieved for full-text assessment for eligibility was included in the final analysis. This study included a total of 186 participants and investigated the effect of LMWH to prevent CVC-related thrombosis compared to standard care. The risk of bias of the study was assessed to be low, except for the unclear risk of selection bias (allocation concealment not reported) and detection bias since it was an open-label study. Nonetheless, outcome adjudication was blinded. However, overall the quality of the evidence was low due to the fact that the study was underpowered. The CIs for the risk of CVC-related thrombosis (symptomatic and asymptomatic events) were compatible with benefits of either LMWH (reviparin) or the control (RR for symptomatic thrombosis 1.03, 95% CI 0.21 to 4.93; RR for asymptomatic thrombosis 1.17, 95% CI 0.45 to 3.08). Similarly, only one patient in the standard care group suffered a major bleeding event, while minor bleeding was found in 53.3% of patients in the reviparin arm and in 44.7% of patients in the standard care arm (major bleeding RR 0.34, 95% CI 0.01 to 8.26; minor bleeding RR 1.20, 95% CI 0.91 to 1.58). Lastly, there were two deaths within the study and neither were the result of a venous thrombotic event (VTE), occurring in the standard care arm. No additional adverse effects were reported. Other pre-specified outcomes for this review were not reported.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-03-07 00:53:21 +0000" MODIFIED_BY="[Empty name]">
<P>A single study reported imprecise effects for the risk of CVC-related thrombosis in children on a CVC anticoagulant prophylaxis regimen. The quality of the evidence was low due to the fact that the included study was clearly underpowered, hampering any conclusions in regards to the efficacy of LMWH prophylaxis to prevent CVC-related thrombi in children. Further prospective randomised studies are highly encouraged.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-03-10 10:13:28 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-03-07 01:24:47 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2014-03-07 01:13:54 +0000" MODIFIED_BY="[Empty name]">
<P>Indwelling central venous catheters (CVCs) were introduced by Broviac et al in 1973 for parenteral alimentation, in hospital or at home (<LINK REF="REF-Broviac-1973" TYPE="REFERENCE">Broviac 1973</LINK>). Later, Hickman et al modified the catheter size and used the catheter for stem cell transplant patients (<LINK REF="REF-Hickman-1979" TYPE="REFERENCE">Hickman 1979</LINK>). Since then, CVCs have been widely used for a variety of indications such as monitoring of haemodynamic status and the administration of parenteral nutrition, blood products and chemotherapeutic agents, or the infusion of other fluids (<LINK REF="REF-Klerk-2003" TYPE="REFERENCE">Klerk 2003</LINK>).</P>
<P>Although advantageous, and at times life saving, the use of CVCs is associated with mechanical and infectious complications. The major mechanical complications observed are occlusion (blockage) and thrombosis (clotting) of the catheter (<LINK REF="REF-Bagnall_x002d_Reeb-1990" TYPE="REFERENCE">Bagnall-Reeb 1990</LINK>; <LINK REF="REF-Bona-2003" TYPE="REFERENCE">Bona 2003</LINK>; <LINK REF="REF-Finkelstein-2004" TYPE="REFERENCE">Finkelstein 2004</LINK>; <LINK REF="REF-Klerk-2003" TYPE="REFERENCE">Klerk 2003</LINK>; <LINK REF="REF-Male-2003" TYPE="REFERENCE">Male 2003</LINK>; <LINK REF="REF-Steele-2001" TYPE="REFERENCE">Steele 2001</LINK>; <LINK REF="REF-Vidler-1999" TYPE="REFERENCE">Vidler 1999</LINK>). The exact incidence of catheter-related thrombosis is unknown but the estimated incidence is 4% to 66% (<LINK REF="REF-Andrew-1995" TYPE="REFERENCE">Andrew 1995</LINK>; <LINK REF="REF-Fratino-2005" TYPE="REFERENCE">Fratino 2005</LINK>; <LINK REF="REF-Krafte_x002d_Jacobs-1995" TYPE="REFERENCE">Krafte-Jacobs 1995</LINK>). Several factors have been implicated in causing CVC-related thrombosis. These include underlying disease, for example, malignancies; the nature of the substances administered, such as chemotherapeutic agents or hyperosmolar solutions that can cause damage to the vascular endothelium; the site of the catheter, with a higher risk in femoral catheters than those inserted in jugular or subclavian veins (<LINK REF="REF-Klerk-2003" TYPE="REFERENCE">Klerk 2003</LINK>); and the type of catheter (<LINK REF="REF-Carde-1989" TYPE="REFERENCE">Carde 1989</LINK>; <LINK REF="REF-Mclean-2005" TYPE="REFERENCE">Mclean 2005</LINK>). The thrombosis related to CVCs can lead to pulmonary embolism, sepsis, stroke or post-thrombotic syndrome (<LINK REF="REF-Anton-2001" TYPE="REFERENCE">Anton 2001</LINK>) and may require long-term anticoagulants.</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-03-07 01:20:25 +0000" MODIFIED_BY="[Empty name]">
<P>The use of anticoagulation prophylaxis to avoid CVC-related thrombosis is a matter of debate in the paediatric population; the best method is not known. Unfractionated heparin (administered intermittently or as a continuous infusion) has been evaluated for the prevention of thrombotic complications in a few paediatric studies (<LINK REF="REF-Randolph-1998" TYPE="REFERENCE">Randolph 1998</LINK>; <LINK REF="REF-Shah-2008" TYPE="REFERENCE">Shah 2008</LINK>). However, the benefits of using unfractionated heparin (UFH) have to be weighted against the risks of allergic reactions, heparin-induced thrombocytopenia (HIT) and bleeding complications secondary to errors in the dosage. On the other hand, low molecular weight heparin (LMWH) has the advantages of having a longer half-life, increased bioavailability, ease of administration and capability for careful monitoring in children (<LINK REF="REF-Anton-2001" TYPE="REFERENCE">Anton 2001</LINK>; <LINK REF="REF-Monagle-2012" TYPE="REFERENCE">Monagle 2012</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2014-03-07 01:24:47 +0000" MODIFIED_BY="[Empty name]">
<P>LMWH, an anticoagulant drug from the family of heparinoids available in several formulations, has been successfully used as a prophylactic regimen for CVCs in adults (<LINK REF="STD-Monreal-1996" TYPE="STUDY">Monreal 1996</LINK>). For example, at a dose of 2500 IU daily given subcutaneously, the LMWH named dalteparin proved to be effective and safe in preventing the development of CVC-related deep venous thrombosis in adult cancer patients. The incidence of venography-proven thrombosis was 6% in the prophylaxis group versus 62% in the placebo group (relative risk (RR) 6.75, 95% confidence interval (CI) 1.05 to 43.58; P = 0.002) and no bleeding complications developed (<LINK REF="STD-Monreal-1996" TYPE="STUDY">Monreal 1996</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2011-09-15 12:30:44 +0100" MODIFIED_BY="[Empty name]">
<P>The prophylactic use of LMWH for CVC-related thrombosis has not been evaluated in children in a systematic manner. The aim of this review was to evaluate the benefits and risks of LMWH for the prevention of CVC-related thrombosis in children.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-03-07 01:28:10 +0000" MODIFIED_BY="[Empty name]">
<P>The primary objective of this review was to determine the effect of LMWH prophylaxis on reducing the incidence of CVC-related thrombosis in children.</P>
<P>Secondary objectives were to determine the effect of LMWH on:</P>
<P>(1) occlusion of CVCs;<BR/>(2) number of days of CVC patency;<BR/>(3) episodes of catheter-related sepsis;<BR/>(4) side effects of LMWH (allergic reactions, major and minor bleeding complications, abnormal coagulation profile, osteoporosis);<BR/>(5) mortality during therapy.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-03-07 08:33:14 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2014-03-07 08:33:13 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2014-03-07 01:31:21 +0000" MODIFIED_BY="[Empty name]">
<P>We included randomised controlled trials of LMWH in children with CVCs and also studies that used alternative methods of randomisation such as alternate days of the week, odd or even date of birth, or hospital number (quasi-randomised). We did not include studies that used historical controls. For any studies in which the unit of randomisation was the catheter, we planned to contact the primary authors to obtain data for the first catheter after randomisation, but this was not required. If in future updates this is required and study authors are unable to provide the data or cannot be contacted, we shall describe the study and include only data on long-term outcomes such as osteoporosis, bleeding complications or mortality.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-03-07 01:33:52 +0000" MODIFIED_BY="[Empty name]">
<P>Children (age one month to 18 years) who required CVCs during their course of treatment either while in hospital or after discharge. The trial participants must have received LMWH versus control (placebo, no treatment, or UFH) without restriction to the specific dose. LMWH, placebo or UFH must have been administered during the entire time the catheter was in place.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-03-07 01:34:28 +0000" MODIFIED_BY="[Empty name]">
<P>LMWH versus control interventions (CVCs without prophylactic heparin, or CVCs with prophylactic UFH) without restrictions on the dose of heparin.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-03-07 08:33:13 +0000" MODIFIED_BY="[Empty name]">
<P>Studies that reported on one or more of the following outcomes amongst the randomised participants.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-03-07 01:41:18 +0000" MODIFIED_BY="[Empty name]">
<P>CVC-related thrombosis (along the length of, or at the tip of, the catheter) as determined by either colour duplex Doppler ultrasonography or contrast venography, with or without clinical suspicion. This was determined as dichotomous data (yes or no). We intended to obtain the time durations of development of catheter-related thrombosis as follows:</P>
<UL>
<LI>within one week of catheter placement;</LI>
<LI>within two weeks of catheter placement;</LI>
<LI>within four weeks of catheter placement;</LI>
<LI>after four weeks of catheter placement.</LI>
</UL>
<P>CVC-related thrombosis could be symptomatic or asymptomatic.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-03-07 01:47:04 +0000" MODIFIED_BY="[Empty name]">
<P>1. Occlusion of the catheter (defined as inability to infuse fluids through the catheter due to blockage). This was determined as dichotomous data (yes or no). We intended to obtain the time durations of development of occlusion of the catheter as follows:</P>
<P>(a) within one week of catheter placement;<BR/>(b) within two weeks of catheter placement;<BR/>(c) within four weeks of catheter placement;<BR/>(d) after four weeks of catheter placement.</P>
<P>2. Days of catheter patency (duration of patency of first catheter, in days).</P>
<P>3. Episodes of CVC-related sepsis (children with one or more episode). CVC-related sepsis was defined as symptoms and signs suggestive of sepsis accompanied by positive blood cultures obtained from a normally sterile site different to a central line, and from the line or catheter tip, each growing the same micro-organism.</P>
<P>4. Side effects of LMWH (allergic reactions, major and minor bleeding complications, abnormal coagulation profile, osteoporosis).</P>
<P>5. Mortality during the period of therapy.</P>
<P>6. Any other reported adverse outcomes (not pre-specified).</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-03-07 01:51:39 +0000" MODIFIED_BY="[Empty name]">
<P>There were no restrictions on language.</P>
<ELECTRONIC_SEARCHES MODIFIED="2014-03-07 01:51:39 +0000" MODIFIED_BY="[Empty name]">
<P>The Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator (TSC) searched the Specialised Register (last searched June 2013) and the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 5), part of <I>The Cochrane Library</I> (<A HREF="http://www.thecochranelibrary.com">www.thecochranelibrary.com</A>). See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for details of the search strategy used to search CENTRAL. The Specialised Register is maintained by the TSC and is constructed from weekly electronic searches of MEDLINE, EMBASE, CINAHL, AMED, and through handsearching relevant journals. The full list of the databases, journals and conference proceedings which have been searched, as well as the search strategies used are described in the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PVD/frame.html">Specialised Register</A> section of the Cochrane Peripheral Vascular Diseases Group module in <I>The Cochrane Library</I> (<A HREF="http://www.thecochranelibrary.com">www.thecochranelibrary.com</A>).</P>
<P>The following trial databases were searched by the TSC for details of ongoing and unpublished studies using the terms catheter and thrombosis and heparin:</P>
<UL>
<LI>World Health Organization International Clinical Trials Registry (<A HREF="http://apps.who.int/trialsearch/">http://apps.who.int/trialsearch/</A>);</LI>
<LI>ClinicalTrials.gov (<A HREF="http://clinicaltrials.gov/">http://clinicaltrials.gov/</A>);</LI>
<LI>Current Controlled Trials (<A HREF="http://www.controlled-trials.com/">http://www.controlled-trials.com/</A>).</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">Authors' searches</HEADING>
<P>We searched MEDLINE (1946 to week 1 July 2013) and EMBASE (1980 to 2013 Week 27). The search strategies can be found in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> and <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.</P>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-06-11 09:53:54 +0100" MODIFIED_BY="[Empty name]">
<P>In addition, we searched the reference lists of identified trials. </P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-03-07 08:33:14 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2014-03-07 01:53:55 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed all published articles identified as potentially relevant by the literature search for inclusion in the review. In order to be included, the trial had to meet the following criteria:</P>
<UL>
<LI>the study population were children (age one month to 18 years);</LI>
<LI>the intervention was LMWH compared with placebo, no treatment or UFH for CVCs;</LI>
<LI>the study was a randomised or quasi-randomised controlled trial;</LI>
<LI>one or more primary or secondary outcome measures were reported.</LI>
</UL>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-03-07 08:33:14 +0000" MODIFIED_BY="[Empty name]">
<P>Two of the review authors (LB, NS) independently extracted data from the retrieved articles. We contacted the primary authors of any articles for which there was inadequate information, or where relevant data could not be abstracted. Discrepancies were resolved by consensus.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-03-07 01:55:47 +0000" MODIFIED_BY="[Empty name]">
<P>The risk of bias of the included study was assessed as per the Cochrane risk of bias tool (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). Two review authors independently performed this evaluation (LB, NS) and discussed disagreements to reach a consensus.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-03-07 01:56:38 +0000" MODIFIED_BY="[Empty name]">
<P>Pre-specified primary and secondary objectives were analysed as dichotomous or continuous outcomes, where relevant and when data were available.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2014-03-07 01:57:18 +0000" MODIFIED_BY="[Empty name]">
<P>No issues related to unit of analysis in the trial design were found since only the parallel group design was encountered.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-05-30 09:03:22 +0100" MODIFIED_BY="[Empty name]">
<P>No imputation for missing data was required.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-03-07 01:58:04 +0000" MODIFIED_BY="[Empty name]">
<P>The Chi<SUP>2</SUP> test of homogeneity, with the significance threshold set at P &lt; 0.10, was planned to be used to detect statistically significant heterogeneity. In addition, we intended to investigate the degree of heterogeneity by calculating the I<SUP>2 </SUP>statistic.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-07-12 22:17:58 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to investigate publication bias using funnel plots if 10 or more studies were identified.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-03-07 02:00:45 +0000" MODIFIED_BY="[Empty name]">
<P>We utilised Review Manager software (RevMan 5.1) to perform data analysis. Statistical methods, where appropriate and data were available, included calculation of risk ratio (RR), risk difference (RD), number needed to treat (NNT) and mean difference (MD). We used 95% confidence intervals (CI) for these estimates of treatment effects. We used a fixed-effect model method based on the inverse variance approach for the analysis.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-03-07 02:01:41 +0000" MODIFIED_BY="[Empty name]">
<P>Given the limited number of studies retrieved, no subgroup analysis was carried out. If sufficient numbers of studies were available we planned to perform the following subgroup analyses according to the control intervention:</P>
<OL>
<LI>LMWH versus placebo, or no treatment;</LI>
<LI>LMWH versus unfractionated heparin.</LI>
</OL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-03-07 02:02:53 +0000" MODIFIED_BY="[Empty name]">
<P>Given the limited number of studies retrieved, no sensitivity analysis was carried out. If in future updates sufficient studies are included we plan to perform a sensitivity analysis to assess the impact of low quality studies on the effects of the intervention by excluding them from the analysis.</P>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings table</HEADING>
<P>We used the principles of the GRADE system (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>) to assess the quality of the body of evidence associated with the outcomes in our review and constructed a 'Summary of findings' (SoF) table using the GRADE software.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-03-07 04:22:24 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-03-07 04:22:24 +0000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2014-03-07 02:04:23 +0000" MODIFIED_BY="[Empty name]">
<P>We retrieved a total of 1487 references from databases, registers and handsearching. All references were saved in an EndNote X6 library, which was used to identify 87 duplicates. One of the review authors (LB) reviewed the remaining 1400 references to check whether they met the inclusion criteria for this review. Twenty-one full-text articles were retrieved for assessment; only one of those 21 articles met the inclusion criteria for this review.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-03-07 03:59:37 +0000" MODIFIED_BY="[Empty name]">
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>One study met the eligibility criteria for this review (<LINK REF="STD-Massicotte-2003" TYPE="STUDY">Massicotte 2003</LINK>). This peer-reviewed manuscript included 186 children randomised to receive either LMWH (reviparin) prophylaxis (mean age 6.1 yr, standard deviation (SD) 5.2 yr) or standard care (mean age 6.4 yr, SD 5.0 yr) for prevention of CVC-related thrombosis (symptomatic or asymptomatic, or both) or thrombosis-related death. Additionally, the most common and relevant complication related to LMWH use, bleeding, was analysed between study arms. The inclusion criteria were neonates, infants and children with a newly placed CVC that were subsequently screened by examination or by imaging at CVC removal (that is day + 30). During CVC placement, patients randomised to the intervention arm received an age-appropriate LMWH dose to prevent thrombosis development. Alternatively, patients randomised to the standard care arm received heparin flushes or heparin infusions at low rates (not equivalent to systemic anticoagulation), a widespread clinical practice to ensure central line patency. The distribution of patients upon randomisation was very clear. The outcomes reported were the rate of CVC-related thrombosis in both arms within 30 days of CVC placement or at the time of CVC removal (+ 14 days if &lt; 30 days).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-03-07 04:22:24 +0000" MODIFIED_BY="[Empty name]">
<P>See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.<BR/>
</P>
<P>A total of 20 full-text articles were excluded or deemed not relevant for this review. A total of 16 studies (16 full-text articles) were excluded for the following reasons: trials run in the adult care setting (<LINK REF="STD-Abdelkefi-2004" TYPE="STUDY">Abdelkefi 2004</LINK>; <LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>; <LINK REF="STD-Karthaus-2006" TYPE="STUDY">Karthaus 2006</LINK>; <LINK REF="STD-Mismetti-2003" TYPE="STUDY">Mismetti 2003</LINK>; <LINK REF="STD-Monreal-1996" TYPE="STUDY">Monreal 1996</LINK>; <LINK REF="STD-Niers-2007" TYPE="STUDY">Niers 2007</LINK>; <LINK REF="STD-Verso-2005" TYPE="STUDY">Verso 2005</LINK>); prospective cohort studies (<LINK REF="STD-Mitchell-2010" TYPE="STUDY">Mitchell 2010</LINK>; <LINK REF="STD-Raffini-2011" TYPE="STUDY">Raffini 2011</LINK>; <LINK REF="STD-Trame-2010" TYPE="STUDY">Trame 2010</LINK>); retrospective cohort studies (<LINK REF="STD-Cavo-2010" TYPE="STUDY">Cavo 2010</LINK>; <LINK REF="STD-Harlev-2010" TYPE="STUDY">Harlev 2010</LINK>; <LINK REF="STD-Harney-2010" TYPE="STUDY">Harney 2010</LINK>; <LINK REF="STD-Sandoval-2008" TYPE="STUDY">Sandoval 2008</LINK>; <LINK REF="STD-van-Ommen-2010" TYPE="STUDY">van Ommen 2010</LINK>) and mixed design (<LINK REF="STD-Vegting-2012" TYPE="STUDY">Vegting 2012</LINK>). A further four full-text articles were deemed not relevant as they were either a review or editorial on the topic.</P>
<P>From the 16 excluded studies, three studies merited a closer look (<LINK REF="STD-Harlev-2010" TYPE="STUDY">Harlev 2010;</LINK> <LINK REF="STD-Mitchell-2010" TYPE="STUDY">Mitchell 2010;</LINK> <LINK REF="STD-Vegting-2012" TYPE="STUDY">Vegting 2012</LINK>). They were reports from two single institution studies (<LINK REF="STD-Harlev-2010" TYPE="STUDY">Harlev 2010;</LINK> <LINK REF="STD-Vegting-2012" TYPE="STUDY">Vegting 2012</LINK>) and from one multicentre collaborative study (<LINK REF="STD-Mitchell-2010" TYPE="STUDY">Mitchell 2010</LINK>). The studies by Harlev (<LINK REF="STD-Harlev-2010" TYPE="STUDY">Harlev 2010</LINK>) and Mitchell (<LINK REF="STD-Mitchell-2010" TYPE="STUDY">Mitchell 2010</LINK>) analysed the incidence of thrombosis in children with the most common form of paediatric cancer, acute lymphoblastic leukaemia (ALL), which is also one of the most common underlying conditions associated with paediatric thrombosis. Interestingly, both studies followed the same chemotherapy protocol, which is one of the considered relevant prothrombotic risk factors in children diagnosed with ALL, allowing comparison of their results. The study by Harlev (<LINK REF="STD-Harlev-2010" TYPE="STUDY">Harlev 2010</LINK>) was a peer-reviewed publication including children treated over a nine-year period (1999 to 2008); their overall thrombosis incidence was 7.5%, and patients carrying an inherited thrombotic risk factor (that is thrombophilia (factor V Leiden or prothrombin gene mutation)) received upfront LMWH prophylaxis (enoxaparin 1 mg/kg/dose, x 1 day) during the most thrombogenic phases of their chemotherapy protocol. The group with thrombophilia and LMWH had a thrombosis incidence of 16.6%, much lower than the previous historical report in the same subpopulation but without LMWH (~ 47%) (<LINK REF="REF-Nowak_x002d_G_x00f6_ttl-1999" TYPE="REFERENCE">Nowak-Göttl 1999</LINK>). The incidence in the low risk patients was 4.5% (<LINK REF="STD-Harlev-2010" TYPE="STUDY">Harlev 2010</LINK>). Half of those thrombotic events occurred in patients with CVCs. The study by Mitchell (<LINK REF="STD-Mitchell-2010" TYPE="STUDY">Mitchell 2010</LINK>) also looked at children with ALL. Thrombosis risk stratification was done using a newly developed thrombosis risk stratification score. Among the elements included in the new scoring system, CVC presence (that is Broviac/Port-a-cath) was included. Four hundred and fifty-six patients were available for scoring and 339 for prospective validation of the score. Subsequently, 8/19 children scoring as high thrombotic risk received LMWH primary prophylaxis prior to CVC placement; LMWH was instituted based on physicians' preferences. This practice led to a significant increased thrombosis-free survival in patients on LMWH (P = 0.02, log rank test). Therefore, both studies suggested a beneficial preventive antithrombotic effect in children with ALL and CVC placement, even in association with other thrombotic risk factors.</P>
<P>Additionally, the study by Vegting (<LINK REF="STD-Vegting-2012" TYPE="STUDY">Vegting 2012</LINK>) was a single centre observational study of children requiring total parenteral nutrition (TPN) administered through a CVC. In this study, patients on TPN receiving either LMWH (for example, nadroparin in a single dose of 80 IU/kg targeting an anti-Xa between 0.1 and 0.3) or an oral vitamin K antagonist (VKA) (acenocumarol, targeting an international normalised ratio (INR) between 2.0 and 3.0) were compared to patients from the same centre in whom anticoagulation prophylaxis was not utilised. The CVC-related outcomes of this cohort were CVC-related thrombosis, infection and obstruction. In sum, patients receiving thromboprophylaxis (n = 18: 16 LMWH, 2 VKA) had a lower rate of thrombosis (6%) in comparison to the children not receiving prophylaxis (n = 14, 33%; P = 0.034). Similarly, cumulative thrombosis-free survival in the thromboprophylaxis and the non-prophylaxis groups was 93% and 48%, respectively (P = 0.04). Moreover, per 1000 TPN days, the prophylaxis and non-prophylaxis groups had 0.1 and 2.6 CVC occlusions (P = 0.04) and 2.1 and 4.6 infections (P = 0.06), respectively, with a three-year infection-free survival of 46% and 19%, respectively (P = 0.03). No bleeding occurred in either group and the study authors concluded that anticoagulation prophylaxis significantly decreased CVC-related complications in children receiving long-term TPN.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-03-07 02:08:54 +0000" MODIFIED_BY="[Empty name]">
<P>The risk of bias of the included study (<LINK REF="STD-Massicotte-2003" TYPE="STUDY">Massicotte 2003</LINK>) is shown in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and is explained in detail in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<ALLOCATION MODIFIED="2014-03-07 02:06:41 +0000" MODIFIED_BY="[Empty name]">
<P>Participants were randomised using a computer-derived protocol. Allocation concealment was judged to be at unclear risk of bias as it was not specifically addressed and the study author has not provided this information.</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-03-07 02:07:20 +0000" MODIFIED_BY="[Empty name]">
<P>This is an open-label study and therefore at high risk of performance bias. However, this situation was ameliorated by the placement of an independent and blinded outcome adjudication process.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-03-07 02:08:28 +0000" MODIFIED_BY="[Empty name]">
<P>For 28 participants (15%) no data were available regarding the efficacy outcome (venogram proven VTE). More specifically, for 23 participants (12 in the intervention arm and 11 in the control arm) the required venogram was not obtained. For the remaining five participants (two in the intervention arm and three in the control arm) the venogram results were inconclusive and hence were not included in the analysis.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-03-07 02:08:44 +0000" MODIFIED_BY="[Empty name]">
<P>The study protocol was not available, but the published report included all expected outcomes.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-03-07 02:08:54 +0000" MODIFIED_BY="[Empty name]">
<P>The study was stopped early due to the low enrolment rate (not due to data-driven reasons) and was underpowered.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-03-07 02:15:26 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">CVC-related thrombosis</HEADING>
<P>No statistically significant difference was evident in the incidence of CVC-related thrombosis (symptomatic and asymptomatic events) between patients in the LMWH (reviparin) arm and the control arm (standard care treatment as described above) (RR for symptomatic thrombosis 1.03, 95% CI 0.21 to 4.93; RR for asymptomatic thrombosis 1.17, 95% CI 0.45 to 3.08) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). However, the study was not powered to detect the efficacy of LMWH prophylaxis to prevent CVC-related thrombosis in children given that its low accrual rate led to early closure of the study.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<P>Only data related to the side effects of LMWH (bleeding events) and mortality were reported in the included study. No further information was available regarding the remaining pre-specified secondary outcomes.</P>
<SUBSECTION>
<HEADING LEVEL="4">Side effects of LMWH</HEADING>
<P>With regard to bleeding events, only one patient in the standard care group suffered a major bleeding event, while minor bleeding was found in 53.3% of patients in the reviparin arm and in 44.7% of patients in the standard care arm (major bleeding RR 0.34, 95% CI 0.01 to 8.26; minor bleeding RR 1.20, 95% CI 0.91 to 1.58) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mortality during period of therapy</HEADING>
<P>Overall, there were two deaths within the study and neither were the result of VTE, occurring in the standard care arm. Because the causes of death were not related to thrombosis, this comparison was not considered for further analysis.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-03-10 10:13:28 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2014-03-07 04:25:46 +0000" MODIFIED_BY="[Empty name]">
<P>The single study included in this review (<LINK REF="STD-Massicotte-2003" TYPE="STUDY">Massicotte 2003</LINK>) reported the incidence of thrombosis in 92 children receiving the LMWH named reviparin and 94 children receiving standard care. This trial found no clear evidence of a difference in the incidence of symptomatic and asymptomatic thrombotic events or major and minor bleeding events between the two study arms. Other predefined outcomes of this review were not reported in the included trial. The included trial was underpowered.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-03-07 04:28:53 +0000" MODIFIED_BY="[Empty name]">
<P>The single trial that met the inclusion criteria (<LINK REF="STD-Massicotte-2003" TYPE="STUDY">Massicotte 2003</LINK>) had a complete report of the primary outcome of this review, CVC-related thrombosis. The study author was contacted to provide additional information on the secondary outcomes intended by this review, including line patency, CVC-related sepsis (as per the criteria defined above), osteopenia and heparin-induced thrombocytopenia (HIT). With regards to the applicability (that is generalisability) of their findings, the most common underlying conditions requiring CVC placement were represented allowing generalisability of the results to paediatric patients admitted to tertiary care hospitals.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-03-07 08:34:14 +0000" MODIFIED_BY="[Empty name]">
<P>The included trial has an adequate methodological design (<LINK REF="STD-Massicotte-2003" TYPE="STUDY">Massicotte 2003</LINK>) and thorough report, including the study limitations and deviations from the protocol. However, it did not adequately describe the method utilised for allocation concealment.</P>
<P>Of note, this was an open-label study, which in theory may increase the estimate of intervention effects. Nonetheless, a committee for outcome adjudication was in place, decreasing the chances of biases in this respect.</P>
<P>In the analysis section of <LINK REF="STD-Massicotte-2003" TYPE="STUDY">Massicotte 2003</LINK>, an intention-to-treat approach was followed for the primary outcome (that is thrombotic events). However, two patients randomised to receive the intervention and who subsequently did not receive the study drug were not included in the final analysis of bleeding events.</P>
<P>Lastly, the study was closed prematurely due to low accrual, yielding an underpowered study. The low number of participants recruited and the wide confidence intervals for the effect estimates prompted us to downgrade the quality of the evidence from high to low (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-03-10 10:13:28 +0000" MODIFIED_BY="[Empty name]">
<P>We searched for published and unpublished abstracts and manuscripts in a comprehensive literature review supervised by an experience librarian and conducted by the authors. This search was not limited to a particular language. Study authors were contacted to fill in data that was missing in the original publications or abstracts. However, a minor limitation of this review is the fact that it was not possible to collect all relevant information from the included trial, particularly efficacy data regarding CVC patency and safety data regarding osteopenia, coagulopathy and allergic reactions secondary to LMWH use, as these outcomes were not included in the study.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-03-07 08:34:38 +0000" MODIFIED_BY="[Empty name]">
<P>Several retrospective and prospective studies have reported the incidence of thrombosis in children with CVCs (<LINK REF="REF-Andrew-1995" TYPE="REFERENCE">Andrew 1995</LINK>; <LINK REF="REF-Monagle-2012" TYPE="REFERENCE">Monagle 2012</LINK>). More recent studies continue to show the rise of thrombotic events in children, particularly due to the higher incidence of CVC-related thrombosis (<LINK REF="REF-Raffini-2009" TYPE="REFERENCE">Raffini 2009</LINK>). In light of the potential morbidity associated with thrombosis-related complications (<LINK REF="REF-Monagle-2012" TYPE="REFERENCE">Monagle 2012</LINK>), prophylaxis with LMWH has increasingly been considered (<LINK REF="STD-Raffini-2011" TYPE="STUDY">Raffini 2011</LINK>) as thrombosis has become a very clinically relevant complication. Nevertheless, in the absence of more convincing prospective paediatric studies, recent guidelines do not support primary prophylaxis for children with CVCs (<LINK REF="REF-Chalmers-2011" TYPE="REFERENCE">Chalmers 2011</LINK>; <LINK REF="REF-Monagle-2012" TYPE="REFERENCE">Monagle 2012</LINK>).</P>
<P>The study conducted by Massicotte et al (<LINK REF="STD-Massicotte-2003" TYPE="STUDY">Massicotte 2003</LINK>) is the only study comparing LMWH with standard care randomly assigned to children from all the main categories of paediatric conditions in which CVC placement is now routine. Even though this study was underpowered, it suggested no difference in the incidence of CVC-related thrombosis despite LMWH prophylaxis. Three other studies of different design suggested differently (<LINK REF="STD-Harlev-2010" TYPE="STUDY">Harlev 2010</LINK>; <LINK REF="STD-Mitchell-2010" TYPE="STUDY">Mitchell 2010</LINK>; <LINK REF="STD-Vegting-2012" TYPE="STUDY">Vegting 2012</LINK>). Because the study population included in the study by <LINK REF="STD-Vegting-2012" TYPE="STUDY">Vegting 2012</LINK>, that is children receiving TPN, is different from the populations of the other two studies, that is children with ALL treated by the same chemotherapy protocol (<LINK REF="STD-Harlev-2010" TYPE="STUDY">Harlev 2010</LINK>; <LINK REF="STD-Mitchell-2010" TYPE="STUDY">Mitchell 2010</LINK>), we should compare the results from the <LINK REF="STD-Massicotte-2003" TYPE="STUDY">Massicotte 2003</LINK> randomised controlled trial with each of the two study groups separately (<LINK REF="STD-Vegting-2012" TYPE="STUDY">Vegting 2012</LINK> and <LINK REF="STD-Harlev-2010" TYPE="STUDY">Harlev 2010</LINK>; <LINK REF="STD-Mitchell-2010" TYPE="STUDY">Mitchell 2010</LINK>).</P>
<P>
<LINK REF="STD-Harlev-2010" TYPE="STUDY">Harlev 2010</LINK> and <LINK REF="STD-Mitchell-2010" TYPE="STUDY">Mitchell 2010</LINK> were not randomised, increasing their chances for biases and study limitations. Similarly, the use of LMWH within their population was not only aimed at preventing CVC-related thrombosis but all types of thrombosis in children with ALL considered at higher risk, of which CVC was included. Notwithstanding, both studies suggested that for this specific paediatric group of ALL patients LMWH may be warranted for the prevention of thrombotic events, including in patients with CVCs. This information is likely to be very relevant for all paediatric populations with a higher risk of thrombosis development, given that CVCs are potentially the most relevant thrombosis risk factor in place (<LINK REF="REF-O_x0027_Brien-2011" TYPE="REFERENCE">O'Brien 2011</LINK>).</P>
<P>In regards to their discrepant findings, the proportions of the two main underlying conditions in <LINK REF="STD-Massicotte-2003" TYPE="STUDY">Massicotte 2003</LINK> were congenital heart disease (22.5%) and cancer (50%). The population of the two excluded cohort studies (<LINK REF="STD-Harlev-2010" TYPE="STUDY">Harlev 2010</LINK>; <LINK REF="STD-Mitchell-2010" TYPE="STUDY">Mitchell 2010</LINK>) was comprised only of children with ALL (cancer), a more homogeneous and maybe more prothrombotic population. Because thrombosis in children is multifactorial, it is plausible that added risk factors are required to trigger such complications. Therefore, populations carrying different risks due to their different nature could vary in their contributions in terms of thrombosis risks, providing a reasonable explanation for the differences noted herein. In fact, even within the same underlying condition, as shown by the study of Mitchell et al (<LINK REF="STD-Mitchell-2010" TYPE="STUDY">Mitchell 2010</LINK>), thrombosis risk stratification is likely to be required for the institution of LMWH-based or any other type of anticoagulant-based prophylaxis.</P>
<P>Secondly, since the anticoagulant effect of LMWH may depend on normal-for-age circulating levels of antithrombin (AT), a natural anticoagulant that potentiates the action of heparin and LMWH, underlying conditions resulting in different degrees of AT consumption may affect the efficacy of LMWH prophylaxis differently, as suggested by a recent study comparing LMWH alone versus LMWH in addition to AT replacement in children with ALL (<LINK REF="REF-Melster-2008" TYPE="REFERENCE">Melster 2008</LINK>).</P>
<P>Thirdly, the study of Massicotte et al (<LINK REF="STD-Massicotte-2003" TYPE="STUDY">Massicotte 2003</LINK>) relied on the combination of Doppler ultrasound (US) and a venogram, the gold standard modality for detection of upper and lower extremity thrombosis in children. This combination is particularly accurate for upper extremity events, which comprise almost 50% of events in children given the relation to CVC placement. The two other studies would have relied on Doppler US alone to diagnose thrombi. Therefore, we could hypothesise that the use of different imaging modalities may have contributed to the disagreements among the studies.</P>
<P>Conversely, the study by Vegting et al (<LINK REF="STD-Vegting-2012" TYPE="STUDY">Vegting 2012</LINK>) was a single centre observational study that combined data obtained retrospectively and prospectively. In this study, CVC-related outcomes encountered in children receiving TPN, with (n = 18) or without (n = 27) anticoagulation prophylaxis, were obtained. Of note, approximately 75% of patients included in the prophylaxis arm were previously included in the non-prophylaxis group as the clinic's anticoagulation policy for children receiving TPN was changed for all patients. Their findings suggested a potential benefit for the use of LMWH in children receiving TPN via a CVC as CVC-related infections, occlusion and thrombosis were less prevalent in patients receiving thromboprophylaxis in comparison to the patients on TPN without thromboprophylaxis.</P>
<P>Once more, the discrepant conclusions between the study by Vegting et al (<LINK REF="STD-Vegting-2012" TYPE="STUDY">Vegting 2012</LINK>) and by Massicotte et al (<LINK REF="STD-Massicotte-2003" TYPE="STUDY">Massicotte 2003</LINK>) may be explained by the multifactorial nature of thrombosis in children. More specifically, the population included in the former study was a much more homogeneous one (100% TPN-dependent) whereas in the latter study the percentage of TPN-dependent patients was not specified but was likely to be equal to or lower than 16% to 21%. Furthermore, children with TPN administered by central venous catheters are recognizably amongst the highest risk groups for CVC-related thrombosis development (<LINK REF="REF-Andrew-1995" TYPE="REFERENCE">Andrew 1995</LINK>). In such patients, the nature of the infusate, leading to local vessel wall inflammation, in addition to protein precipitation within the catheter lumen contribute to a likely high rate of CVC-related complications.</P>
<P>Depending on the time of CVC insertion, thrombosis risk factors will have greater or lesser importance. Given the study design of the first study (<LINK REF="STD-Vegting-2012" TYPE="STUDY">Vegting 2012</LINK>), the interpretation of the results has significant limitations as 13/18 patients from the thromboprophylaxis arm had already had their CVC inserted and been exposed to TPN for a considerable time before they entered "the intervention study arm", likely leading to exposure to risk factors in an unbalanced and different manner. Similarly, a younger age also predisposes children to CVC-related thrombotic complications and hence the same study limitation applies. Therefore, while the study findings suggest that LMWH is safe and beneficial in terms of CVC-related outcome prevention for children receiving TPN, further prospective studies with a more appropriate design are required. Because of the particular characteristics of TPN-related thrombotic events, mentioned herein, the generalisibility of such findings to children with a CVC and who are not receiving TPN requires caution, likely contributing to the discrepant results as shown by the randomised controlled trial (<LINK REF="STD-Massicotte-2003" TYPE="STUDY">Massicotte 2003</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-03-07 05:27:31 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-03-07 05:19:30 +0000" MODIFIED_BY="[Empty name]">
<P>A single study reported imprecise effects for the risk of CVC-related thrombosis in children on a CVC anticoagulant prophylaxis regimen. The quality of the evidence was low due to the fact that the included study was clearly underpowered, hampering any conclusions in regards to the efficacy of LMWH prophylaxis to prevent CVC-related thrombi in children.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-03-07 05:27:31 +0000" MODIFIED_BY="[Empty name]">
<P>Since the reported incidence of symptomatic CVC-related thrombosis in children is approximately 10%, a trial evaluating the superiority of LMWH prophylaxis in comparison to standard care will require at least 856 patients in total (that is 428 patients per arm in a one to one allocation) to achieve 80% power to detect a 50% relative risk reduction of symptomatic thrombosis, which can be considered clinically meaningful. The two-sided significance level (1-alpha) was set at 95. Open-Epi software was utilised for the sample size calculation.</P>
<P>Therefore, other multicentre randomised trials are required to answer this question, a task not completed by the reported manuscript (<LINK REF="STD-Massicotte-2003" TYPE="STUDY">Massicotte 2003</LINK>). However, many lessons can be learned from this report (that is the relatively large number of exclusions, responsible for 31% of problems with enrolment). Given the increasing placement of CVCs in modern paediatric care, and that paediatric hospital accreditation may be conditioned to the development of age and scenario-specific prophylaxis protocol development in the near future, there will be a continued need to conduct trials evaluating this problem. Trials should aim to evaluate the role of patient age, risk factors, and of additional prophylactic modalities such as new oral anticoagulant agents, warfarin and CVC flushes. Lastly, the potential cost of any prophylactic intervention should also be addressed in future studies.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-03-07 05:28:16 +0000" MODIFIED_BY="[Empty name]">
<P>We acknowledge Ms Elizabeth Uleryk for her invaluable expertise in developing the authors' search strategy.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-08-05 09:02:21 +0100" MODIFIED_BY="[Empty name]">
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-03-07 05:28:53 +0000" MODIFIED_BY="[Empty name]">
<P>LR Brandão selected trials, assessed trial quality, extracted data and wrote the final review.<BR/>N Shah selected trials, assessed trial quality, extracted data, and wrote and edited the final review.<BR/>PS Shah assessed trial quality, collaborated using his methodological expertise and edited the final review.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-03-07 05:29:19 +0000" MODIFIED_BY="[Empty name]">
<P>The planned assessments of the methodological quality of the included studies has been replaced by the risk of bias tool from The Cochrane Collaboration (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>).</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-03-07 05:44:33 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-02-26 09:52:01 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-02-26 09:51:07 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Massicotte-2003" MODIFIED="2014-02-26 09:51:07 +0000" MODIFIED_BY="[Empty name]" NAME="Massicotte 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-02-26 09:51:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Massicotte P, Julian JA, Gent M, Shields K, Marzinotto V, Szechtman B, et al; PROTEKT Study Group</AU>
<TI>An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial</TI>
<SO>Thrombosis Research</SO>
<YR>2003</YR>
<VL>109</VL>
<NO>2-3</NO>
<PG>101-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-02-26 09:52:01 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abdelkefi-2004" MODIFIED="2013-05-30 13:31:39 +0100" MODIFIED_BY="[Empty name]" NAME="Abdelkefi 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-05-30 13:31:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abdelkefi A, Ben Othman T, Kammoun L, Chelli M, Romdhane NB, Kriaa A, et al</AU>
<TI>Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological disease. A randomized controlled trial</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2004</YR>
<VL>92</VL>
<NO>3</NO>
<PG>654-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cavo-2010" MODIFIED="2011-11-07 01:30:06 +0000" MODIFIED_BY="[Empty name]" NAME="Cavo 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-09-01 04:23:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cavo M, Wang W, O'Brien SH</AU>
<TI>Use of low molecular weight heparin for thromboprophylaxis in a pediatric inpatient population: reasons for use and incidence of bleeding complications</TI>
<SO>Thrombosis Research</SO>
<YR>2010</YR>
<VL>125</VL>
<NO>4</NO>
<PG>370-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Cicco-2009" MODIFIED="2013-05-30 13:32:09 +0100" MODIFIED_BY="[Empty name]" NAME="De Cicco 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-05-30 13:32:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Cicco M, Matovic M, Balestreri L, Steffan A, Pacenzia R, Malafronte M, et al</AU>
<TI>Early and short-term acenocumarine or dalteparin for the prevention of central venous catheter-related thrombosis in cancer patients: a randomized controlled study based on venographies</TI>
<SO>Annals of Oncology</SO>
<YR>2009</YR>
<VL>20</VL>
<NO>12</NO>
<PG>1936-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harlev-2010" MODIFIED="2014-02-26 09:52:01 +0000" MODIFIED_BY="[Empty name]" NAME="Harlev 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-02-26 09:52:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harlev D, Zaidman I, Sarig G, Ben Arush MW, Brenner B, Elhasid R</AU>
<TI>Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment</TI>
<SO>Thrombosis Research</SO>
<YR>2010</YR>
<VL>126</VL>
<NO>2</NO>
<PG>93-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harney-2010" MODIFIED="2014-02-26 09:50:18 +0000" MODIFIED_BY="[Empty name]" NAME="Harney 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-02-26 09:50:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harney KM, McCabe M, Branowicki P, Kalish LA, Neufeld EJ</AU>
<TI>Observational cohort study of pediatric inpatients with central venous catheters at "intermediate risk" of thrombosis and eligible for anticoagulant prophylaxis</TI>
<SO>Journal of Pediatric Oncology Nursing</SO>
<YR>2010</YR>
<VL>27</VL>
<NO>6</NO>
<PG>325-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-08-29 01:58:09 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karthaus-2006" MODIFIED="2013-06-13 07:50:39 +0100" MODIFIED_BY="[Empty name]" NAME="Karthaus 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-06-13 07:50:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karthaus M, Kretzschmar A, Kroning H, Biakhov M, Irwin D, Marschner N, et al</AU>
<TI>Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial</TI>
<SO>Annals of Oncology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>2</NO>
<PG>289-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mismetti-2003" MODIFIED="2014-02-26 09:47:57 +0000" MODIFIED_BY="[Empty name]" NAME="Mismetti 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-02-26 09:47:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mismetti P, Mille D, Laporte S, Charlet V, Buchmüller-Cordier A, Jacquin JP, et al; CIP Study Group</AU>
<TI>Low molecular weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial</TI>
<SO>Haematologica</SO>
<YR>2003</YR>
<VL>88</VL>
<NO>1</NO>
<PG>67-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mitchell-2010" MODIFIED="2014-02-26 09:47:31 +0000" MODIFIED_BY="[Empty name]" NAME="Mitchell 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-02-26 09:47:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mitchell L, Lambers M, Flege S, Kenet G, Li-Thiao-Te V, Holzhauer S, et al</AU>
<TI>Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study</TI>
<SO>Blood</SO>
<YR>2010</YR>
<VL>115</VL>
<NO>24</NO>
<PG>4999-5004</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monreal-1996" MODIFIED="2013-05-30 13:34:35 +0100" MODIFIED_BY="[Empty name]" NAME="Monreal 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-05-30 13:34:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, et al</AU>
<TI>Upper extremity deep venous thrombosis in cancer patients with venous access devices--prophylaxis with a low molecular weight heparin (Fragmin)</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1996</YR>
<VL>75</VL>
<NO>2</NO>
<PG>251-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niers-2007" MODIFIED="2011-11-07 02:26:43 +0000" MODIFIED_BY="[Empty name]" NAME="Niers 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-11-07 02:26:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niers TM, Di Nisio M, Klerk CP, Baarslag HJ, Buller HR, Biemond BJ</AU>
<TI>Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2007</YR>
<VL>5</VL>
<NO>9</NO>
<PG>1878-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raffini-2011" MODIFIED="2013-06-13 08:36:25 +0100" MODIFIED_BY="[Empty name]" NAME="Raffini 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-06-13 08:36:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raffini L, Trimarchi T, Beliveau J, Davis D</AU>
<TI>Thromboprophylaxis in a pediatric hospital: A patient-safety and quality-improvement initiative</TI>
<SO>Pediatrics</SO>
<YR>2011</YR>
<VL>127</VL>
<NO>5</NO>
<PG>e1326-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sandoval-2008" MODIFIED="2013-06-13 08:37:52 +0100" MODIFIED_BY="[Empty name]" NAME="Sandoval 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-06-13 08:37:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sandoval JA, Sheehan MP, Stonerock CE, Shafique S, Rescorla FJ, Dalsing MC</AU>
<TI>Incidence, risk factors and treatment patterns for deep venous thrombosis in hospitalized children: an increasing population at risk</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2008</YR>
<VL>47</VL>
<NO>4</NO>
<PG>837-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trame-2010" MODIFIED="2013-06-13 08:39:41 +0100" MODIFIED_BY="[Empty name]" NAME="Trame 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-06-13 08:39:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trame MN, Mitchell L, Krümpel A, Male C, Hempel G, Nowak-Göttl U</AU>
<TI>Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2010</YR>
<VL>8</VL>
<NO>9</NO>
<PG>1950-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Ommen-2010" MODIFIED="2013-06-13 08:40:41 +0100" MODIFIED_BY="[Empty name]" NAME="van Ommen 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-06-13 08:40:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Ommen CH, Tabbers MM</AU>
<TI>Catheter-related thrombosis in children with intestinal failure and long-term parenteral nutrition: how to treat and to prevent?</TI>
<SO>Thrombosis Research</SO>
<YR>2010</YR>
<VL>126</VL>
<NO>6</NO>
<PG>465-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vegting-2012" MODIFIED="2013-08-05 09:09:27 +0100" MODIFIED_BY="[Empty name]" NAME="Vegting 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-08-05 09:09:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vegting IL, Tabbers MM, Benninga MA, WIlde JC, Serlie MJ, Tas TA, et al</AU>
<TI>Prophylactic anticoagulation decreases catheter-related thrombosis and occlusion in children with home parenteral nutrition</TI>
<SO>Journal of Parenteral and Enteral Nutrition</SO>
<YR>2012</YR>
<VL>36</VL>
<NO>4</NO>
<PG>456-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verso-2005" MODIFIED="2013-05-30 13:37:14 +0100" MODIFIED_BY="[Empty name]" NAME="Verso 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-05-30 13:37:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verso M, Agnelli G, Bertoglio S, Di Somma FC, Paoletti F, Ageno W, et al</AU>
<TI>Enoxaparin for prevention of thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>18</NO>
<PG>4057-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-03-07 05:44:33 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-03-07 05:44:33 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Andrew-1995" NAME="Andrew 1995" TYPE="JOURNAL_ARTICLE">
<AU>Andrew M, Marzinotto V, Pencharz P, Zlotkin S, Burrows P, Ingram J, et al</AU>
<TI>A cross-sectional study of catheter-related thrombosis in children receiving total parenteral nutrition at home</TI>
<SO>Journal of Pediatrics</SO>
<YR>1995</YR>
<VL>126</VL>
<NO>3</NO>
<PG>358-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anton-2001" NAME="Anton 2001" TYPE="JOURNAL_ARTICLE">
<AU>Anton N, Massicotte MP</AU>
<TI>Venous thromboembolism in pediatrics</TI>
<SO>Seminars in Vascular Medicine</SO>
<YR>2001</YR>
<VL>1</VL>
<NO>1</NO>
<PG>111-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bagnall_x002d_Reeb-1990" NAME="Bagnall-Reeb 1990" TYPE="JOURNAL_ARTICLE">
<AU>Bagnall-Reeb HA, Ruccione K</AU>
<TI>Management of cutaneous reactions and mechanical complications of central venous access devices in pediatric patients with cancer: algorithms for decision making</TI>
<SO>Oncology Nursing Forum</SO>
<YR>1990</YR>
<VL>17</VL>
<NO>5</NO>
<PG>677-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bona-2003" NAME="Bona 2003" TYPE="JOURNAL_ARTICLE">
<AU>Bona RD</AU>
<TI>Central line thrombosis in patients with cancer</TI>
<SO>Current Opinion in Pulmonary Medicine</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>5</NO>
<PG>362-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Broviac-1973" NAME="Broviac 1973" TYPE="JOURNAL_ARTICLE">
<AU>Broviac JW, Cole JJ, Scribner BH</AU>
<TI>A silicone rubber atrial catheter for prolonged alimentation</TI>
<SO>Surgery, Gynecology and Obstetrics</SO>
<YR>1973</YR>
<VL>136</VL>
<NO>4</NO>
<PG>602-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carde-1989" MODIFIED="2013-05-30 13:37:55 +0100" MODIFIED_BY="[Empty name]" NAME="Carde 1989" TYPE="JOURNAL_ARTICLE">
<AU>Carde P, Cosset-Delaigue MF, Laplanche A, Chareau I</AU>
<TI>Classical external indwelling central venous catheter versus totally implanted venous access systems for chemotherapy administration: a randomized trial in 100 patients with solid tumors</TI>
<SO>European Journal of Cancer and Clinical Oncology</SO>
<YR>1989</YR>
<VL>25</VL>
<NO>6</NO>
<PG>939-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chalmers-2011" MODIFIED="2013-06-13 09:04:36 +0100" MODIFIED_BY="[Empty name]" NAME="Chalmers 2011" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers E, Ganesen V, Liesner R, Maroo S, Nokes T, Saunders D, et al; British Committee for Standards in Haematology</AU>
<TI>Guidelines on the investigation, management and prevention of venous thrombosis in children</TI>
<SO>British Journal of Haematology</SO>
<YR>2011</YR>
<VL>154</VL>
<NO>2</NO>
<PG>196-207</PG>
<IDENTIFIERS MODIFIED="2011-10-24 06:49:15 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Finkelstein-2004" MODIFIED="2013-05-30 13:38:44 +0100" MODIFIED_BY="[Empty name]" NAME="Finkelstein 2004" TYPE="JOURNAL_ARTICLE">
<AU>Finkelstein Y, Yaniv I, Berant M, Zilber R, Garty BZ, Epstein O, et al</AU>
<TI>Central venous line thrombosis in children and young adults with thalassemia major</TI>
<SO>Pediatric Hematology and Oncology</SO>
<YR>2004</YR>
<VL>21</VL>
<NO>5</NO>
<PG>375-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fratino-2005" MODIFIED="2013-06-13 09:07:24 +0100" MODIFIED_BY="[Empty name]" NAME="Fratino 2005" TYPE="JOURNAL_ARTICLE">
<AU>Fratino G, Molinari AC, Parodi S, Longo S, Saracco P, Castagnola E, et al</AU>
<TI>Central venous catheter-related complications in children with oncological/hematological diseases: an observational study of 418 devices</TI>
<SO>Annals of Oncology</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>4</NO>
<PG>648-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2014-03-07 05:42:36 +0000" MODIFIED_BY="[Empty name]" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ, et al</AU>
<TI>What is "Quality of evidence" and why is it important to clinicians?</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7651</NO>
<PG>995-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hickman-1979" MODIFIED="2013-06-13 09:09:29 +0100" MODIFIED_BY="[Empty name]" NAME="Hickman 1979" TYPE="JOURNAL_ARTICLE">
<AU>Hickman RO, Buckner CD, Clift RA, Sanders JE, Stewart P, Thomas ED</AU>
<TI>A modified atrial catheter for access to the venous system in marrow transplant recipients</TI>
<SO>Surgery, Gynecology and Obstetrics</SO>
<YR>1979</YR>
<VL>148</VL>
<NO>6</NO>
<PG>871-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2013-08-05 09:07:33 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<ED>Higgins JPT, Green S</ED>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klerk-2003" MODIFIED="2013-06-13 09:14:04 +0100" MODIFIED_BY="[Empty name]" NAME="Klerk 2003" TYPE="JOURNAL_ARTICLE">
<AU>Klerk CP, Smorenburg SM, Büller HR</AU>
<TI>Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2003</YR>
<VL>163</VL>
<NO>16</NO>
<PG>1913-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krafte_x002d_Jacobs-1995" MODIFIED="2014-02-26 09:41:05 +0000" MODIFIED_BY="[Empty name]" NAME="Krafte-Jacobs 1995" TYPE="JOURNAL_ARTICLE">
<AU>Krafte-Jacobs B, Sivit CJ, Mejia R, Pollack MM</AU>
<TI>Catheter-related thrombosis in critically ill children: comparison of catheters with and without heparin bonding</TI>
<SO>Journal of Pediatrics</SO>
<YR>1995</YR>
<VL>126</VL>
<NO>1</NO>
<PG>50-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Male-2003" MODIFIED="2014-03-07 05:44:33 +0000" MODIFIED_BY="[Empty name]" NAME="Male 2003" TYPE="JOURNAL_ARTICLE">
<AU>Male C, Chait P, Andrew M, Hanna K, Julian J, Mitchell L; PARKAA Investigators</AU>
<TI>Central venous line-related thrombosis in children: association with central venous line location and insertion technique</TI>
<SO>Blood</SO>
<YR>2003</YR>
<VL>101</VL>
<NO>11</NO>
<PG>4237-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mclean-2005" NAME="Mclean 2005" TYPE="JOURNAL_ARTICLE">
<AU>McLean TW, Fisher CJ, Snively BM, Chauvenet AR</AU>
<TI>Central venous lines in children with lesser risk acute lymphoblastic leukemia: optimal type and timing of placement</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>13</NO>
<PG>3024-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Melster-2008" MODIFIED="2014-02-26 09:46:16 +0000" MODIFIED_BY="[Empty name]" NAME="Melster 2008" TYPE="JOURNAL_ARTICLE">
<AU>Meister B, Kropshofer G, Klein-Franke A, Strasak AM, Hager J, Streif W</AU>
<TI>Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia</TI>
<SO>Pediatric Blood and Cancer</SO>
<YR>2008</YR>
<VL>50</VL>
<NO>2</NO>
<PG>298-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Monagle-2012" MODIFIED="2014-02-26 09:45:36 +0000" MODIFIED_BY="[Empty name]" NAME="Monagle 2012" TYPE="JOURNAL_ARTICLE">
<AU>Monagle P, Chan AK, Goldenberg NA, Ichord RN, Journeycake JM, Nowak-Göttl U, et al</AU>
<TI>Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th Edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines</TI>
<SO>Chest</SO>
<YR>2012</YR>
<VL>141</VL>
<NO>2 Suppl</NO>
<PG>e737S-801S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nowak_x002d_G_x00f6_ttl-1999" MODIFIED="2013-06-13 09:31:27 +0100" MODIFIED_BY="[Empty name]" NAME="Nowak-Göttl 1999" TYPE="JOURNAL_ARTICLE">
<AU>Nowak-Göttl U, Wermes C, Junker R, Koch HG, Schobess R, Fleischhack G, et al</AU>
<TI>Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors</TI>
<SO>Blood</SO>
<YR>1999</YR>
<VL>93</VL>
<NO>5</NO>
<PG>1595-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Brien-2011" MODIFIED="2014-02-26 09:44:55 +0000" MODIFIED_BY="[Empty name]" NAME="O'Brien 2011" TYPE="JOURNAL_ARTICLE">
<AU>O'Brien SH, Candrilli SD</AU>
<TI>In the absence of a central venous catheter, risk of venous thromboembolism is low in critically injured children, adolescents, and young adults: evidence from the National Trauma Data Bank</TI>
<SO>Pediatric Critical Care Medicine</SO>
<YR>2011</YR>
<VL>12</VL>
<NO>3</NO>
<PG>251-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Raffini-2009" MODIFIED="2013-05-30 13:41:54 +0100" MODIFIED_BY="[Empty name]" NAME="Raffini 2009" TYPE="JOURNAL_ARTICLE">
<AU>Raffini L, Huang YS, Witmer C, Feudtner C</AU>
<TI>Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007</TI>
<SO>Pediatrics</SO>
<YR>2009</YR>
<VL>124</VL>
<NO>4</NO>
<PG>1001-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Randolph-1998" NAME="Randolph 1998" TYPE="JOURNAL_ARTICLE">
<AU>Randolph AG, Cook DJ, Gonzales CA, Andrew M</AU>
<TI>Benefit of heparin in central venous and pulmonary artery catheters:a meta-analysis of randomized controlled trials</TI>
<SO>Chest</SO>
<YR>1998</YR>
<VL>113</VL>
<NO>1</NO>
<PG>165-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shah-2008" MODIFIED="2014-02-26 09:44:28 +0000" MODIFIED_BY="Maria L Avila" NAME="Shah 2008" TYPE="COCHRANE_REVIEW">
<AU>Shah PS, Shah VS</AU>
<TI>Continuous heparin infusion to prevent thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-02-13 10:03:57 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-13 10:03:57 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002772.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Steele-2001" NAME="Steele 2001" TYPE="JOURNAL_ARTICLE">
<AU>Steele R, Irvin CB</AU>
<TI>Central line mechanical complication rate in emergency medicine patients</TI>
<SO>Academic Emergency Medicine</SO>
<YR>2001</YR>
<VL>8</VL>
<NO>2</NO>
<PG>204-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vidler-1999" NAME="Vidler 1999" TYPE="JOURNAL_ARTICLE">
<AU>Vidler V, Richards M, Vora A</AU>
<TI>Central venous catheter-associated thrombosis in severe haemophilia</TI>
<SO>British Journal of Haematology</SO>
<YR>1999</YR>
<VL>104</VL>
<NO>3</NO>
<PG>461-4</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-03-07 05:35:34 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-03-07 05:33:20 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-03-07 05:32:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Massicotte-2003">
<CHAR_METHODS MODIFIED="2011-09-06 07:42:26 +0100" MODIFIED_BY="[Empty name]">
<P>Open-label randomised controlled trial of low molecular weight heparin for prevention of CVC-related thrombosis in children</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-07 05:30:48 +0000" MODIFIED_BY="[Empty name]">
<P>Newborns &gt; 36 weeks gestational age to children &lt; 18 years; if age &lt; 36 weeks, then weight &gt; 5 kg at randomisation</P>
<P>CVC placed for the first time</P>
<P>The neonates, infants and children with a newly placed CVC were subsequently screened by examination or by imaging at CVC removal (i.e. day + 30)</P>
<P>Age: LMWH (reviparin) prophylaxis mean age: 6.1 yr (standard deviation (SD) 5.2 yr); standard of care mean age: 6.4 yr (SD 5.0 yr)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-07 05:31:10 +0000" MODIFIED_BY="[Empty name]">
<P>Reviparin: 30 IU/kg if &lt; 3 months; 50 IU/kg if &#8805; 3 months (dose as per previous age-appropriate pharmacokinetic findings)</P>
<P>Control/comparison:<B> </B>Unfractionated heparin flushes or very low doses infusion of unfractionated heparin (&lt; 3 IU/kg/hour)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-07 05:32:12 +0000" MODIFIED_BY="[Empty name]">
<P>Primary:</P>
<P>CVC-related venous thromboembolism (VTE) detected by an exit venogram at day + 30 (+ 14 d) or at the time of CVC removal (+ 14 days) if &lt; 30 days,</P>
<P>a confirmed symptomatic VTE within 30 d of CVC placement, or death due to thrombosis during the study period</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-03-07 05:32:42 +0000" MODIFIED_BY="[Empty name]">
<P>Underpowered, closed prematurely due to low enrolment rate</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-03-07 05:35:34 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-07-18 12:08:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abdelkefi-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-18 12:08:28 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective randomised trial in adults with haemato-oncological conditions receiving heparin infusion for thrombosis prevention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-07 01:51:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cavo-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-07 01:51:14 +0000" MODIFIED_BY="[Empty name]">
<P>Retrospective cohort study of patients receiving low molecular weight heparin prophylaxis identified as per ICD-9-CM codes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-07 05:34:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Cicco-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-07 05:34:00 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective randomised trial comparing short-term prophylaxis with either dalteparin or low dose acenocumarine in adults with cancer for prevention of venography-proven catheter-related thrombosis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-07 01:51:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harlev-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-07 01:51:16 +0000" MODIFIED_BY="[Empty name]">
<P>Retrospective cohort study of paediatric patients with acute lymphoblastic leukaemia, either receiving or not LMWH prophylaxis according to the practice of different periods of time</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-07 05:34:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harney-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-07 05:34:30 +0000" MODIFIED_BY="[Empty name]">
<P>Retrospective cohort study in paediatric patients with CVC admitted to intensive care unit</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-07 02:29:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karthaus-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-07 02:29:54 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective, double-blinded, placebo-controlled study in adult cancer patients receiving dalteparin to prevent central venous catheter-related thrombosis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-18 12:08:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mismetti-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-18 12:08:30 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective, open-label, randomised trial comparing the LMWH nadroparin to low dose warfarin in adult cancer patients with central venous catheters</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-13 03:00:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mitchell-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-13 03:00:10 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective paediatric cohort study for validation of a clinical predictive model for thrombosis development in children with acute lymphoblastic leukaemia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-18 12:08:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Monreal-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-18 12:08:30 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective open-label, randomised trial enrolling only adults with cancer and central catheter devices receiving dalteparin as prophylaxis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-18 12:08:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Niers-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-18 12:08:31 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective, randomised, double-blinded, placebo-controlled study in adult patients with hematologic cancer receiving nadroparin for prevention of catheter-related thrombosis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-07 01:51:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Raffini-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-07 01:51:37 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective study to assess compliance to thromboprophylaxis guidelines in children</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-07 01:51:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sandoval-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-07 01:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Retrospective cohort study on risk factors for thrombosis in hospitalised children</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-07 01:51:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trame-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-07 01:51:41 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective study for the evaluation of pharmacokinetic of enoxaparin in children</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-07 05:35:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Ommen-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-07 05:35:18 +0000" MODIFIED_BY="[Empty name]">
<P>Retrospective cohort study for prophylaxis candidates among children on long-term parenteral nutrition</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-07 05:35:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vegting-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-07 05:35:34 +0000" MODIFIED_BY="[Empty name]">
<P>Observational study for anticoagulation prophylaxis of children receiving total parenteral nutrition, including a retrospective and a partly prospective source of data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-30 09:18:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Verso-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-30 09:18:36 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blinded, placebo-controlled study in adult cancer patients receiving enoxaparin for central venous catheter-related thrombosis prevention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-03-07 05:33:20 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-09-01 06:45:08 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-01 06:45:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Massicotte-2003">
<DESCRIPTION>
<P>Quote: "They were randomly assigned by a computer-derived protocol to receive..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-09-01 06:37:52 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-01 06:37:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Massicotte-2003">
<DESCRIPTION>
<P>Not enough information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2011-09-06 07:42:43 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-09-06 07:42:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Massicotte-2003">
<DESCRIPTION>
<P>Quote: "The PROTEKT trial was an open-label randomised controlled trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2011-09-06 07:42:46 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-09-06 07:42:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Massicotte-2003">
<DESCRIPTION>
<P>Quote: "An independent and blinded Central Adjudication Committee assessed all efficacy and safety outcomes."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-03-07 05:33:20 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-03-07 05:33:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Massicotte-2003">
<DESCRIPTION>
<P>Missing outcome data balanced between study arms (for thrombotic events: 14/92 for reviparin arm versus 14/94 for standard of care arm; for bleeding events: 2/92 reviparin arm versus 0/94 for standard of care arm), with similar reasons for missing outcome data (quote: "For 23 patients (12 receiving reviparin-sodium and 11 standard care), the mandatory venogram was not done, usually because of an inability of the patient to be transported to the radiology department. For the other five patients (two reviparin-sodium, three standard care), the venograms were indeterminate."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-09-01 07:08:54 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-01 07:08:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Massicotte-2003">
<DESCRIPTION>
<P>The study protocol is not available, but the published report includes all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-09-06 07:43:38 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-06 07:43:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Massicotte-2003">
<DESCRIPTION>
<P>The study was stopped early due to low enrolment rate (not due to data-driven reasons)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-03-07 05:38:03 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-03-07 05:38:03 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-05-30 09:30:02 +0100" MODIFIED_BY="[Empty name]">Low molecular weight heparin for prevention of central venous catheter (CVC)-related thrombosis in children</TITLE>
<TABLE COLS="6" ROWS="25">
<TR>
<TD COLSPAN="6">
<P>
<B>Low molecular weight heparin for prevention of central venous catheter (CVC)-related thrombosis in children</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population: </B>Children<B> </B>with central venous catheter</P>
<P>
<B>Settings: </B>Paediatric tertiary hospital</P>
<P>
<B>Intervention: </B>Low molecular weight heparin</P>
<P>
<B>Comparison: </B>Control (placebo, no treatment or standard of care for central venous catheter (unfractionated heparin (UFH) flushes or low dose UFH)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Control</P>
</TH>
<TH VALIGN="TOP">
<P>Low molecular weight heparin</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>CVC-related symptomatic thrombosis</B>
</P>
<P>Venography §</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.03 </B>
</P>
<P>(0.21 to 4.93)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>158<BR/>(1 study)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>low#</B>
</P>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>38 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>39 per 1000</B>
<BR/>(8 to 185)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>Low risk population</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>75 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>77 per 1000</B>
<BR/>(16 to 370)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>CVC-related asymptomatic thrombosis</B>
</P>
<P>Venography §</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.17</B>
</P>
<P>(0.45 to 3.48)<BR/>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>158<BR/>(1 study)</P>
<P>
<BR/>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>low#</B>
</P>
<P>&#8853;&#8853;&#8861;&#8861;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>88 per 1000</B>
<BR/>
</P>
</TD>
<TD>
<P>
<B>102 per 1000</B>
<BR/>(30 to 305)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>Moderate risk population</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>300 per 1000</B>
<BR/>
</P>
</TD>
<TD>
<P>
<B>351 per 1000</B>
<BR/>(135 to 1000)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>Side effects of LMWH: major bleeding</B>
</P>
<P>Clinical findings</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.34</B>
</P>
<P>(0.01 to 8.26)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>184</P>
<P>(1 study)</P>
<P>
<BR/>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>low#</B>
</P>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>11 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>4 per 1000</B>
</P>
<P>(0 to 88)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>Low risk population</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>10 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>3 per 1000</B>
<BR/>(0 to 83)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>Side effects of LMWH: minor bleeding</B>
</P>
<P>Clinical findings</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.2</B>
</P>
<P>(0.91 to 1.58)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>184<BR/>(1 study)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>low#</B>
</P>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>436 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>523 per 1000</B>
<BR/>(397 to 689)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>Low risk population</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>300 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>360 per 1000</B>
<BR/>(273 to 474)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Mortality during period of therapy</B>
</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Not estimable</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>184<BR/>(1 study)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>low#</B>
</P>
<P>&#8853;&#8853;&#8861;&#8861;</P>
</TD>
</TR>
<TR>
<TD>
<P>See comment^</P>
</TD>
<TD>
<P>See comment^</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)</P>
<P/>
<P>§ Follow up for less than five to more than 30 days</P>
<P># Underpowered study; study was closed prematurely due to slow recruitment rate</P>
<P>^ There were 2 deaths during the study period, both were unrelated to thrombosis and occurred in the standard of care arm</P>
<P>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk Ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-03-07 05:46:53 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2014-03-07 05:46:38 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>LMWH versus standard care for CVC: thrombosis</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2013-07-18 12:26:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="7.19" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="78" TOTAL_2="80" WEIGHT="0.0" Z="0.0">
<NAME>Symptomatic thrombosis</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.928019275117511" CI_START="0.21346091700359487" EFFECT_SIZE="1.0256410256410255" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6926723978294214" LOG_CI_START="-0.6706816292264951" LOG_EFFECT_SIZE="0.010995384301463145" MODIFIED="2011-09-01 05:39:29 +0100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.8008409042039211" STUDY_ID="STD-Massicotte-2003" TOTAL_1="78" TOTAL_2="80" VAR="0.6413461538461539" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2013-07-18 12:26:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="151.36" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="78" TOTAL_2="80" WEIGHT="0.0" Z="0.0">
<NAME>Asymptomatic thrombosis</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.0774225806353157" CI_START="0.4464651108261534" EFFECT_SIZE="1.1721611721611722" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.4881871361035004" LOG_CI_START="-0.35021247354520046" LOG_EFFECT_SIZE="0.06898733127914997" MODIFIED="2011-09-01 05:41:06 +0100" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.4924800808526473" STUDY_ID="STD-Massicotte-2003" TOTAL_1="78" TOTAL_2="80" VAR="0.24253663003663" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-03-07 05:46:53 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>LMWH versus standard care for CVC: bleeding events</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2013-07-18 12:26:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="78" TOTAL_2="80" WEIGHT="0.0" Z="0.0">
<NAME>Major bleeding</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.264392818842627" CI_START="0.014133912360406122" EFFECT_SIZE="0.34177215189873417" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9172109516627335" LOG_CI_START="-1.8497376059256418" LOG_EFFECT_SIZE="-0.46626332713145413" MODIFIED="2011-09-01 05:47:00 +0100" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="1.6253192793436677" STUDY_ID="STD-Massicotte-2003" TOTAL_1="78" TOTAL_2="80" VAR="2.6416627598062195" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="48" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2013-07-18 12:27:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="25.47" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="78" TOTAL_2="80" WEIGHT="0.0" Z="0.0">
<NAME>Minor bleeding</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5832108748309623" CI_START="0.9106820271565462" EFFECT_SIZE="1.200750469043152" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="41" LOG_CI_END="0.19953876431030182" LOG_CI_START="-0.04063323439567191" LOG_EFFECT_SIZE="0.07945276495731494" MODIFIED="2011-09-01 05:47:54 +0100" MODIFIED_BY="[Empty name]" ORDER="6" O_E="0.0" SE="0.1410782209104564" STUDY_ID="STD-Massicotte-2003" TOTAL_1="78" TOTAL_2="80" VAR="0.019903064415259544" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-03-07 05:33:21 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-02-19 08:52:51 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAcwAAAP6CAYAAAAdZ20fAAB+h0lEQVR42uydD2RX3x//vyTJZCL5
mExiJpPMyGSSiST5+MpIPpKvr0gmk4lMZmZiZmZmPmSSmUSSJImZfEwSmZnJxEySJCaZTM7v+zy/
33n/zvvu3nvufe+9tT+PB2/b+33uPX/uOef1vOfc1z3nX8bjX//6Fx8+m/Kz0aBO+PDZvP03sV/7
HRxgs7KR2i99CWBr9pl/0cGBTodYAtB3MuWRDg50OsQSANFEMIEOR2cHoP8imAAIJgD9F8EEQDAB
6L8IJgCCCQAIJgCCCQAIJmw0pqenuQgIJtBX6L+/UzBv3rxp9uzZY3bv3m1aWlrM58+fM4cvLi5u
6hUdVluBofPKeS127dqVGPezZ8/Mzp07TX19fVnS3QQNekOmndZXvn//bi5dumTrcd++faatrc18
+/aNvrKF+0o0Ldjkgtnb22sGBwfNr1+/7Ke7u9ucPHkyc/jTp0+tYaAC1z7etLjUKZ8/f76dGvSG
SzvUV65cuWLu3LlTCB8YGDDnz5+nr2zhvlLutBDM3yyYhw4dMj9+/FhRyVnDZRTU8fNcqNevX5v9
+/ebhoaGwu9dXV2msrLSVFRU2Dtvn58/f9o7c92119bWmsnJyRV39TpP4TJQHz9+TE1PxuratWt2
JFBVVWXGxsZi70B37Nhhjhw5YiYmJjJVfCjeUDl17MjIiKmurrZp+50tbgTv/00Ky5JulnzT4cJp
h/qKRj261v511zWnr2zNvpI065a3DvTb3bt37azE3r17zYMHD0xfX5/Nw2YV5C3xDFPTq2osFy9e
zByuO+RTp07ZBqYKVGMIXajW1lbb8D59+mR/Gx4eto1fvy0vL9tGqDtxx+3bt83Dhw8LI9rDhw8X
wtRw/Lt6xSWDkZZef3+/6enpsb99+fLFNDU1FVWg3whfvHhhDWGWig/FGyqnjj137lyhAykPvsGN
1qH/PS0slG4o33S4/GnH9ZWoYErcolOH9JWt1VeiYaXUgX67fPmyzc+TJ0+sndVshb5Hy41grpNg
Xrhwwd716PPu3bvM4X/88Ye5f/9+4e7r77//tp027UL5d1RC8/u+IXF36w51+mi4o66uzhoe3wjp
TiwtPd25+ee8ffu2qAJ1d+eMTp6KD8UbKmdcXrN29LSwULqhfNPh8qWd1FdkGDUbo7pYWloy169f
t6Mj+srW7SvRsFLqIPqbvuuGbLOIz5YdYbrpAk2tlBquxiYRzXOhdIcUnb7wDUnaHVScwUm704yL
T3n2j9Odsr6r83R2dmau+FC8oXLG5bUcRiDv9Y3mmw5XWtrRviIHH4mprndNTY1tZ6ERJn1lc/eV
aFgpdZCWXwTzNwumhvlpnS4UntQo0i5U2vEhIxAXltY5spwj9BxBU1qnT5827e3tJRmBaHionGtl
BEq5vgjm6tMO9ZWZmRn7HIy+snX7SjSslDpAMDeQYGpKRXPxSVMEoXD9L3d5P1zOBnkulO7C/SmG
KLobT5pm0rnRKQ7/rj0uvcbGxqJzZLiSrs/U1FTmDhGKN1TOtTICoXTzXA86XHLaob4S5dGjR4n+
AvSVrdFXomGl1AGCuYEEU9NGmkpxD6Fv3bplP1nDb9y4YZ0bXLgekA8NDeW6UHoQ7h6k66Pvvju+
nolq6keMj4+vcGRwz4X0UdoyGmnpjY6OWu9e9+C+ubm56DjFL+8/EXqo7p8XijdUzlBnkVednmW4
DpfVCITSDeWbDpct7VBfUbuSSIoPHz7YEZmegdFXtm5fiXP6yVsHCOYGEkxNG8krS3c5clKIermG
wuW8II8thcvlWY2tlAvV0dFhvb8Uj7zfnIeYS0Pveqoz6qF51Mg4N2195FgxNzcXTE/vzOnuX969
8lTzj9MUk9Jx7urOIGQpT1q8oXKGOotuRnSeuyPNagRC6WbJNx0unHaor6jdymnEPcMMOcvQVzZ/
X4kLy1sHCOYGEkyAzQhL4wHQfxFMAAQTgP6LYAIgmAD0XwQTAMEEAAQTgA6HYAIgmAB0OAQTgD6E
YAIdDsEEoP8imECHo7MD0H8RTAAEE9aH6elpLgJ9KF0w3Qaw2m3gd/H161e7UavW4nQrlGgfuugF
Tvr4x0TPi1ZO1nj8j/KklT+uXr1atG6uQ0uQ6biXL19uKeO6kfO+EQVTbUNbdmkVGLUZbQulZSM3
4jUJLfi9HnnK28/W+rqk7RwDCKbld+/YrY6h5cK0aatb9/HNmzfm4MGD5t69e7kusI5RXFoeLEvl
5Pld+dRODNptPcq///1vG/bnn38imNtYMLWQuvaGdYufqz1rGbTQpupb+frlXTYurZ8xc4Bg/lbB
jBth6a/Wh9RoT+LjcOsfalFjLUYc3dD07t279s5a68k+ePDALjKsu8WQIGuxaB0bRaLpp59VMLWB
dXRfvnIIppAh1DXw0TqTBw4csP9L5D9//ryqhuFG/FqbUzsbTExMFIVrxKI1LJUPjcp9tKC31r5U
HSkO7Rrz+PHjorxE61ZGXetZ6hwdPzk5WXS8Foqurq4urBX6O2+uNrpgxi08LgFQn/DP1Y2g+orq
UGvPRm/w0uo4VF952kLc/6tpf+ofEjr1e21bptmevIKZ1M/S0nXhSlfXenBwMHf5kmab0tJNspWw
hUeYcQv5qhOr0bpFhyVoaoRuhX0tOKxO659z+fJlu/j0kydPbMPVguz6HtrBQLsdLCwslOUCu2OO
HTu2QtDLIZgi2pG1c4HbkUKLNken4PI2DF+UtOuEv9u7rrtG4qoDXVsZJC0y7Th69KjdTcHVk+pM
nTmtbnXD4hYB156G/u4WOv7s2bOFaxmqy+0umLp2qg9/+6a4c/X4Q9dU9aD2omncrHUcqq88bSHu
/9W0v/7+/sJOH9rJo6mpqSTBjPazULoK06jUpXv8+PGSyhfNTyjduP4E21AwfbEReqYY3cPN3+cv
eo6++3vKpV2crAY467NH8erVK7uzfTkFU6Iug6AO4qPRl+7mxfz8vB1lrqZhyKgl7WIhQxvd69Dv
8HFEd6mP1q0MbtL+iXHHb5SGvhEFUzuDqD7UpnWjodkOtcXouf6o8MePH4UZiix1HKqvPG0h7v/V
tD+Nsnw7oeuRVzDj+lkoXe1R6c/sRNPNWr5ofkLpxvUP2IaCmdbR4oRuNdvPaMqoXBfYP0aC6YxV
KYIZ/WiKSdPSutN06A7V3ytPaH883/knb8NQnG4UEp1a1jWP5itaN5oi0ihEz9N0oxNy7si6fyGC
mT1t1YGMvqZEdX21HZR/btQI+3UQquM89ZW1Lfj/r6b9RfOmcuZx+knqZ6F0o8460XSzli+a11C6
PPNEMDMb1Tz7y6VdHE0d+bvUO9Rhkp65ZKkE3alqana1I0zduZ45c8buJh9FBjGu0+v31TQMGTpN
t2mDYU01pd24+OjZmEYgep4s0dY0EYL5e9PWqwpp037ROgjVcdb6ytMW4oS2lPYXshOl9rO86aYJ
Zlr5oseF0kUwEczYgujheHRK1r+rW41g6i5PzwmiyNtQzyJKFUwXt6bFVjslK/GWCOr5rENTMZqO
jY4W9F2/uymi1TQMGQ//fNWDP9UdRc+O/XBNEYcEUxsZ55niQzCT05bDSdy19J/H6VxfFL59+2br
LWsdZ62vPG0hqTx525+mRn07MTMzk2tKNq6fZUlXN8b+Tfe7d+9KKl/0uFC6CCaCGVsQOf3IW9I5
EAwNDdmOWw7BlMHQdJHi1PMcxf/o0SNrfPznP6UIprwPNfVSjmeYEkCNFGR4nBjHefcKTcE555+8
DUOjArdrfdTJRuk5pwp99N2fEpZQu1G5jJUMSchwaMpO01RC75MmOZEgmOG0NZWoOnFObGp/6jf+
8zidqzqTgVcdymHs/Pnzmes4a33laQv+/6tpf3IykhOcc77R44m8zzCj/SxLulGnH4WVUj49HtKN
sBP9ULoIJoKZagx0p6yPPGTn5ubKIphu+vSvv/6ycWsaRM4DMgbROLI6/fikubbn/V15OnHihP1f
U8nR1wEcEn7dnWbNd3S6SDcQ7jUO17kd8sTV6EEjfN2N+955usFwTicyDHJuCF0flaGlpaWwYIQc
JhDM0tPWjZJuJlV/coxTv/FHXTpXQvbHH39YB5QbN27Ym8asdZy1vvK0Bf//1bQ/d7OocutVDHmZ
luIl6/ezrOlKqJWmnoEq3aQZsLTyyQNW5/nnpqWLYG5DwQSgw61f2vTDtUc3Fb7nMdB/EUygwyGY
8D80opUTj3tfUqN635kH6L8IJtDhNmHarFdafuQFrMc4urbyfdA0t/9aCtB/EUygw9HZAei/CCYA
gglA/0UwARBMAPovggmAYAIAgglAh0MwARBMADocgglAH0IwgQ6HYAIgmAgm0OHo7AD0XwQTAMEE
oP8imAAIJgD9F8EEQDABAMEEQDABAMEEoMMhmAAIJgAdDsEEoA8hmECHQzAB6L8I5nZmenqai4Bg
0nZg09fpphfMpaUlU1NTs+L3Hz9+mKtXr5qKigq7QWtLS4v59u1bIXxxcdEWPvrZLhUYOq+c1yK6
+bAf97Nnz8zOnTtNfX19WdLdBA16w6X9/ft3c+nSJVtP+/btM21tbUV9ZT3K7Yf7/6e1HW4wsAfr
XYebWjC1O/n58+djC3H9+nUzNDRkfv36ZT83b960oul4+vRp0XfueNYu3rS41DmeP3++nRr0hkv7
ypUr5s6dO4W+MjAwYPvV7xJMRuTYg416PTa1YJ48edIsLCzEFmLv3r228/vi6t/ZdHd3W8OQ50K9
fv3a7N+/3zQ0NBR+7+rqMpWVlXYkqztzn58/f9o79927d5va2lozOTlZFC4R13kKV1k+fvyYmp7K
c+3aNbNnzx5TVVVlxsbGYu/OduzYYY4cOWImJiYyVXwo3lA5dezIyIiprq62afuNPm4E7/9NCsuS
bpZ8I5jhtNUv/L6i/3VNk/jw4YM5d+6cbbeqa7Xtx48fZ66XUHie9hHqQ0ntMks50uoKe7A97cGm
FsyXL19mLoQaqxqbQ3fQp06dshdfF1iNNXShWltbbaV8+vTJ/jY8PGwbhn6TIKuCdKfuuH37tnn4
8GFhRHv48OFCWF9fnxkcHCzc1Ssudaa09Pr7+01PT4/97cuXL6apqamo7H7DfPHihTl06FCmig/F
GyqnjpXhcR1ceVBekhpZ0vRb9Hso3VC+EczSBFN9JTpt5nP06FEzOjpaaLtqx37fCtVLKDxr+8jS
h9LaZagcIcHEHmw/e7AlnH6yHHP//n3bYB1//PGH/c3dmfz9999F4XFp+Hd8QvPsvqERfqNUh4iG
O+rq6qxh8o2Unh+lpac7S/+ct2/fFpVdnd11yDzXLBRvqJxxec3aCdLCQumG8o1gZktbhlmzLbrW
8gnQ4wyNDPLgHx+ql1B41vZRSh8KXX+/HCHBxB5sP3uwLQTz69ev5sKFC/auJAlVhEQ0Txq6a4pO
I/gdzr+rSuuYcccnpRfNs3+c7iL1XQ2rs7Mz8zULxRsqZ1xey9FB8l7faL4RzGxpy8FH/UPXUw50
akdpI0yh6UHdYF68eNEa+7ztKS08a/sopQ9Ff0srR0gwsQfbzx5secGUSP711192iJ7nLjlLGqG7
8LQOEhcW6qyhc5wB0HTP6dOnTXt7e0kdJIthCl2bcnSQUq4vgrn6tGdmZuwzoCTu3btnR0t37961
j0U0RZinPeVp+yEDmrcP+b+FypFXMLEHW98ebGnB1MhSr5bMz8+vCNN0h9zp/SkQPYjPk4YepOv1
lCR0t540BaNzo1Mw/l19XHqNjY1F58iwJZV9amoqc4cPxRsq51p1kFC6ea4Hgpk97UePHtkRVxJ6
5u/Xi/pXnvYUCs/TPvL2If+3UDnyCib2YOvbgy0rmP/88485ceKE+fz5c+w5N27csB5X7iG7Hh7r
NZQ8aehBvXvIrI++y7vNoakeTYuI8fHxFQ/53XMjfZS2/z5pXHpyUJB3r3uo3dzcXHSc4pdnnIg+
aE8rTyjeUDlDHURef3qm4RpzHqeOtHRD+UYws6WtdiORFPIc1WhEz3+SkPej8yaVUTp27Fiu9hQK
z9p2SulD/m+hcuQVTOzB1rcHW1YwDxw4kLowgZwb9P6Z7uL0CooqopQL1dHRYe9UFY88w5wHm0tD
73qqoer5SNQIOTdyfeR4MTc3F0yvt7fXjo7l3SuvMf84Tb8oHefK7TpLlvKkxRsqZ6iD6GZE57k7
5qwdJJRulnwjmOG01S7lMOGeYYYcRV69emWdLXS8jLKOz9ue0sKztp1S+pD/W6gceQUTe7D17QFL
4wEwJQsACCYAHQ7BBEAwAehwCCYAfQjBBDocgglA/0UwgQ5HZweg/yKYAAgmAP0XwQRAMAHovwgm
AIIJAAgmAIIZw/T0NBUDsJUF022OqpX4fwdaRsvfbNZHy4wp3L/ISZ+0Y+J2H8+zc73+155xoWNC
eaMBb23BjO5MshGv6e/O0+9Ofy3s3e+2oQjmOgpmnJis94WTKGq5Kx+tj6iNabMusZV2jMqndRf9
cuYVTC15Fs1j3rzRgLe2YIaWI6Oefz9rYe9+tw3F3qyTYMaNhPRXaydq01SJhMOtzyjh0UK9/sam
Okdb+2jtQa0n++DBA7ugr9YqDDUmnat1C7XxtI82pdbec+UQTCeaoX3x0sRQ+YvuhbdawXR3plqj
UjsITExMFIVrUXut5ajr3tbWVhSmxb21BqTqQ3Fohxh/pB5Xj7oJ0dqaOkfHT05OFh2vRau1kLZb
M3MjG4GNJphJfSntmpba10L5UbtR31NfHBwcXNFO89RzUh7j2qZ2LdLa03E3v2rfSXmNa+MHDx60
uyQJt/vJmzdv7HdtBKHwJJKuX5aZnzzlTYszre/mTcOdMzIyklhvaX07FHfIDiGYgbvi1tZWu1K9
W5BX4qeO51a312K8qhz/nMuXL9s9M588eWI7qxZk1/csq/urQxw/frzod+308P79+7IJZl6BiztW
I+Ek41VKA/AbvXZf8Hc91zVWB9H11nXUlLAWW3Zo9K1dBVydqH7UAdPqUbs8uAXBtbefv8uDjj97
9myhfKF6QzCz9aW0a1pqX0tLV21G+zW6nSbUr6LtNE89x+UxrW1qG0CVwae/v98a7Ghe0+LR3rtu
5xfdgGu6W8e77/418Snl+q2mvHFxZjm+lDR0g5xUb2l9OxR3mh1CMDN0cl8UhFbqj+4xp9Fk0jn6
7u+3lkXE1LElkO4OUoIQJ0pZnmGulWBqV4YLFy4kHpP3GaYELmlHCz0Pie75F2rI0d3ao/WoTpS0
j2Dc8Ru5UW8WwUy7pqX2tbR0tZehvxWfdvIIpRnqM9Hj09rm7OysHWW6cP3VaNAf5WWJR5tSS3zF
f//7X7uvqNtbVDfncT4FpV6/1ZQ3Ls4sx5eSRlq9pfXtUNxpdgjBzNDJ0wyxf1eSNY4sIqZpolu3
bhXuSN0d0EYaYQoJpoSzHCNM3c3pPDXo6HSvrm9UeKP1oGkd3VnKkMhQlLKzfJ6pPgQzv2DmbYN5
+1r0t6jjkQxlKM2822+F2qb2z9WIRmgWRCOjuPjS4pHwuptmTRNq42YJsdCUY9xm9qVev9WWN3pO
3uNLPSd6LdNmstLiTrNDCGYJnTyuMvLsvZalQ2pqoqqqynZwVZzrEBtNMBcWFgqeu+Vw+pHoaQpF
U9CaSkvr+D66A9ddpZ4dv3z50l4/BHPzC2bevhYynGshmKG2qfYsUXNip/YZF18oHj2D1bSyE0o9
v9MG1e57kjiUq99nzWf0nLzHl3pOVsEMxZ1mhxDMEjq5Gn10msO/ky2HYAo9oNcoU9NKpTT2tGNW
6/Tjo7swOQGV00tWd9B+HLrm/rR2FD0n9sOdY0RafrSpcdqULIL5+wUzb1+L1rtu5iQyjnfv3pVd
MENt04mbZoqizjl52vj58+fNf/7zn8JUrJuWdd/jyHv9ylHe6Dl5jy/1HP+3tL6dpb6S7BCCWUIn
14N0TZm6B+lDQ0O2gsotmHo4rbshdbRyCqa8wOQ95u+UvhrBlBegRsGrFUyNEF2eooKua97T01O4
5vquGwrfIDmvWN11y1CG8qPpW02/iPHx8RVOPwjm6tJWG9NzJmewSxHMUF/zHTQ026HpzjSnH7WZ
cgtmqG0KPVLRjJHvXBKNLxSProOeP+oaCN2k6hq76d448tqqcpQ3ek7e40s9x/8trW+H4k6zQwhm
CYIpnKu2PvI6m5ubK7tgfvv2zQqm8xyLMzDlXLggLa6QkZHTwWqdfjQNomePzk3cF3TR0dFhR5K6
Q5Zh9K+LnqPqwb3OU4PXQ/tQniX0LS0t9hylK4cQBLN8aUscVFduRFOKYIb6mjNoajMSArWZaDzd
3d32FQIJlm5CQyOsvIIZaptCr4QozB/txsWXFs8///xT9DqJc2ByzoFJ5LFV5Shv3Dl5jy/lHP+3
tL4dijtkhxBMgE0Oa8lmQ4Y07ZkfAH0IwQQ63Lbs7JrClPOGe+dOo631cOIAQDAB6HCbqrPLI1Wr
x2jqTV6mN27csMIJQP9FMIEOR2cHoP8imAAIJgD9F8EEQDAB6L8IJgCCCQAIJgCCCQAIJgAdDsEE
QDAB6HAIJgCCiWACHY7ODkD/RTABEEwA+i+CCYBgAtB/EUwABBMAEEwABBMAEEwAOhyCCYBgAtDh
EE0A+g6CCXQ6Oj4A/RbB3J5MT09zETZYx1M++PDhk+2ziexLfGa/f/9uLl26ZDec1W7tbW1t5tu3
b6kGYceOHZnP3+oGOHReORuJrnFS3M+ePTM7d+409fX1ZUl3Ezxj4K4BaB+wvoJ55coVc+fOHfPr
1y/7GRgYMOfPn0+M6MmTJ6ajo6Pk87dbBytnvGlxSSyfP3++bQwOBhFoH7DugqlRi4TOof/37NkT
e6zCjh49akeVpZzvGvLr16/N/v37TUNDQ+H3rq4uU1lZaSoqKuwo1efnz592FLt7925TW1trJicn
i8Jv3rxpz1P4yZMnzcePH1PTUx6vXbtm81lVVWXGxsZiR2saSR85csRMTExk6piheEPl1LEjIyOm
urrapu2LYNzUhv83KSxLulnyjUEEBBMQzIjgSZyiU3+O4eHhotFl3vNdQ25tbbXnfPr0qRCvhEK/
LS8vW4OtUavj9u3b5uHDh/b/p0+fmsOHDxfC+vr6zODgYGGEq7gkrmnp9ff3m56eHvvbly9fTFNT
U1EH84XqxYsX5tChQ5k6ZijeUDl17Llz5wqCrzwoL0lGwP+eFhZKN5RvDCIgmIBg/g+Ji6ZRZSyX
lpbM9evXi55R+mh0OT8/X/L5riH7I0Ch526+6ApfpCSQ0XBHXV2dFWlfsPUsNS09jTT9c96+fVvU
wTQadQKdp2OG4g2VMy6vWUUxLSyUbijfGERAMAHB/B9y0Llw4YIdydTU1NgRVdwIcXZ21hw7dqzk
89Mass5NcyzyR1lR4sQ5bVQWF5/ExD9OZdB3CU1nZ2fmjhmKN1TOuLyWQzDzXt9ovjGIgGACghnD
zMyMfY4VRaNIPSss9fy0hpw2Ig0JZlxYmpBkOUfouaemf0+fPm3a29tLEsxoeKicayWYpVxfBBMQ
TEAwAzx69MhcvHhxxe/yfJWAlHp+WkOWY83i4mLiORq5Jk3J6tzolKw/wo1Lr7GxsegciXzS9Zma
mkrtfH5YKN5QOddKMEPp5rkeGERAMGHbCqaeD0rkxIcPH+yISs+wouiZl3OaKeX8tIYsxx3ndKKP
vsvb1SGnH02TivHx8RVOP+4Zqj5DQ0NWYNPSGx0dNd3d3QUnl+bm5qLjFL88ZUXU8SatPKF4Q+UM
Caa8gPWM04lbVsEMpRvKNwYREExAMM3/dfCQ04d7Bpnk7KLwuFFe1vNDDVnet3qtQaNDeYr64ixn
opaWFpuGnHyiguxeK9FHTkhzc3PB9Hp7e61zkF61kBepf5ymY5WOe7XDiWeW8qTFGypnSDDl2arz
3Ag6q2CG0s2SbwwiIJiw7QUTAIMItA8ABBMwiED7AEAwAYMIQPsABBMAgwi0D0AwATCIQPsABBMA
gwi0D0AwATCIQPsABBMAgwi0D6D90IAAgwi0D4CSBdNtlqydOX5Xw076OLRLyuPHj2PP17J8/i4q
0Ti0nJyW6/NX/3FomT0d8/LlyxVh2iRbW5Vp9RtdHy0NqE2Y8+Ydo0LegfYBW0Qw/c2SN2rD1jES
RS2R56M1VbVHZ9oScTpG66Rqqbso//73v+1OJH/++eeKMC0gf//+/cJygIpHS/D5O7Zs9k6JYAKC
CZBRMONGRfqrtVS1ibLWiHW49Vo1YtPC3f5Gxzrn7t27djS2d+9e8+DBA7vAt9YuDQlyVsHUWqd/
//130e8SNO1XGdrOSyjfPlpL9cCBA/b/gwcPms+fP6+4kYgbdap8q+mUbkSvdWq1i8jExERRuEax
Ws9V17qtra0oTIvbax1YlUVx1NbWFo284+pOQq/1dXWOjp+cnCw6XgvXV1dXF9bN/Z03TxhEoH3A
hh5hxi3a3draakdWboFuid/g4GBhtwstzi0j7J9z+fJls7y8bJ48eWKF8sqVK/Z7nt0+0o6Zn583
x48fL/pdU63v379PFUzlVzt1qAw+GnXeunXL/q+FyaPTrdqxRIud+9telaNT+qKkHVg01evQdR0Z
GbF51rUbGxuzeXBoNK2dRVw9qE4kjml1p51e3IL42p7N3+lFx589e7Zw8xOqKwwiIJiAYEa++6NH
oenM6J6TGk0mnaPv/v6Lof0kQ88B3f8STAmk0IhQAhKNPykujUZ9NKrSiE1IjDXK9NGOKBIzCYhE
RaPbV69e5c57FAlc0o4ueo4c3RHGF9Q4/M2h4+pOApm0l2jc8Tx/BQQTaD85BDPNKPsjpaxxZN2A
OXSMpg/dqLC/v78w+gqNMDUq03SkQyM7fz9IoT0g45x/NMWptDQVqjJrang1nVJp6zyJo6aTo9c0
KrzRa6/8aNSoZ6y6kQlNR+cd3SOYgGAC7WcVghlndPPsxVguwdQ0Y1VVlRVBCY5GhqG8ONwekkLi
Fzcq1O9pTE9PF434Su2UEj1Nj2pKWU5HaTcmPvfu3bMjRj0vlrjreiCYALQP2ECCKeeU6JSsL0Dr
JZhCI0ONMhsbGzOJt9DzQDeFrClITcdGpyn1Xb875x8598RNZcoZp1ydcmpqqigOXWd/KjuKng37
4bphCJVdm3qnTckimIBgApRRMOUwo+lQ52wyNDRkDfHvEEw5xmgkpmnSLIKpV1EksG4kp2nQqAOQ
Q9OtzvlHXsE6bmFhoRCProGcalbTKTVClKesiDrZKD05KLnrrO/+1LEE3XnFzszM2FdtQoKp6VtN
Awu9dxp1+kEwAcEEKKNgOgHR6Eofecj6CwGsVjCzOv2Ib9++WcF0XqBxgul/NFKUyLl3OOUoFH2f
0/Hjxw87ynNIPHVjoPQ0QtU18EfapTj9aDpWzx7daxxOPB3y2NVIUiN4TRH75ZTTkXNEkvDJeSgk
mCprS0uLPUfpypkJwQQEE6AEwQTAIALtAwDBBAwi0D4AEEzAIALQPgDBBMAgAu0DEEwADCLQPgDB
BMAgAu0DEEwADCLQPgDBBMAgAu0DaD80IMAgAu0DAMEEDCIA7QMQTAAMItA+AMEEwCAC7QMQTAAM
ItA+AMEEwCAC7QMQTAAMItA+AMEEwCAC7QMgrv3QiABjCLQRgIyCSUMCDCHQTgAyCqZrTHz4bMYP
AIIJ6yqYQEcFoB8CIJh0VAD6IRcBEEw6KgDQDwHBpKMCAP0QEEw6KgDQDwHBBDoqAP0QEEygowLQ
DwHBBDoqAP0QAMGkowLQDwEQTDoqANAPAcGkowIA/RAQTDoqANAPAcGkowIA/RAQTKCjAtAPAcEE
OioA/RAQTKCjAtAPARBMOioA0A8BwaSjAgD9EBBMOioA0A8BwaSjAgD9EBBMiOuofPjw+f0fAAQT
gNEJACCYAAgmACCYAAgmACCYAAgmACCYAAgmACCYAIBgAgCCCYBgAgCCCYBgAgCCCYBgAgCCCYBg
AgCCCYBgAgCCCbB1hZL1SAGAng+AYAIAgglQftEEAAQTABBMAEAwARBMAEAwARBMAEAwATaKaAIA
ggkACCYAIJibzzDz4cMn2wcAwWQUAwD0GUAwgY4PQN8BBBPo8AD0IUAwgc4OQB8CBBPo7AD0IQAE
k84OQB8CQDDp7AD0IQAEk84OAPQhQDCBzr5pmJ6e5iJs0OtAHwIEE8G0LC0tmZqamtRjHj58uCKe
b9++mXPnzpndu3ebiooKc+HCBfPly5fM4dv9huPZs2dm586dpr6+3n7ftWvXpiuPH1e54l2v64Bg
AoIJuTr78vKyOX/+fOoxCwsL5uTJkyuO6erqMp2dnebXr1/2c//+fdPR0ZE5fLsLpsTy+fPn626U
10owt7I4IZiAYCKYVggliGnHnD592rx//37FMadOnTIzMzNF4nvmzJnM4XH5fP36tdm/f79paGgo
Et7Kyko7Sm1rays65+fPn+bSpUt2FFtbW2smJyeLwm/evGnPU7jK+vHjx9T0JOzXrl0ze/bsMVVV
VWZsbKyo3G5UuGPHDnPkyBEzMTGRWJ4PHz4URtg6R/l7/PhxIe0sa5imlT3pevmEyhNX79Hwe/fu
mX379tk8tLa22hmJ0AgzrV7yXJcs1yFPnSCYgGBCyZ395cuXqcd0d3ebwcHB2GNkhGWQo79lDY/L
pwyyzvn06ZP9bXh42IyMjNjfJLgy+Hfu3Cmcc/v2bTtdLJ4+fWoOHz5cCOvr67N5dyNcxSUjnpZe
f3+/6enpsb9p+ripqamo3P6o8MWLF+bQoUOJ5Tl69KgZHR0tpK+8SNyS6iX6PVT2uPxHCZUni2Bq
ylg3GopDwnX9+vWgYKbVS97rEroOeeoEwQQEE1bd2eOOefPmjR0lJh0jQxXF/y0UHpcHfwQoZKyj
ousbRBniaLijrq7OjnT8UY9GSmnpaaTmn/P27duicsuwOyEoBY2CsgpmqOxx+Y8SKk8WwfRHhz9+
/DAHDhwICmZaveS9LqHrsNo6QTABwYRVCeb379+tsf38+XPiMb6RixPEUHiWfOr46DSdH29afKH0
k9LzkaH2j9MIxo269Hw2hKZMNdq6ePGiFfA0sYq7IUkre5Z6DZUni2BGxSrpGkZH4uW6LqHrkLdO
EExAMKGsgnn58mXz6NGj1GPiplejU7Jp4VnyGSd6WQU4LiwkFqFznLHXNKOe7ba3tyemr2d/Gmnd
vXvXTn1r2jSPYIbKXopgZrkGea5RKYKZ97qErkOeOkEwAcGEsgtmFocUGSdN0TnkDCLHmqzhWfIp
J47FxcXEc/Q6TNLUn86NTsn6ryzEpdfY2Fh0jpyWkq7f1NRU6rXVzYGf9/n5+VyCGSp7lnoNlSca
R1weVU6HXhXyb3qS4kqrl7zXJXQd8tQJggkIJpRdMLMcIwcQ51Cij0YM/pRYKDxLHuS448eh777o
alpPU3JifHx8hdPPwMBA4dyhoaGi903j0pMzihydnJNMc3Pzimdz8soUcjRJG0lVV1cXvD8lVMeO
HUsVBnmN6pmkE7hQ2bPUWag8vsOMvKXlvRrNo9LUuYrj1q1b9jWkkGCm1UvouuS9DnnqBMEEBBN+
i2BqKk0GWKM2fc6ePWtHIFnDs+ZB725qVKI4ZNB9j1CNWltaWqyR1LMwObX4uNdK9JGH7NzcXDC9
3t5e6xyk1xjkoekfp6k/paNpQqXpDHUcr169ss4pOk5GPbr4QzR9eX66a5Wl7FmNeFp5nMCoPLqZ
UHmieZS4/fHHH9a55saNG0V1mFSetHoJXZe81yFPnSCYgGACnR1oO1wHQDCBzg60Ha4DIJhAZ4cN
zEZc15U+BAgm0NkB6EOAYAKdHYA+BIBg0tkB6EMACCadHYA+RB8CBJPODgD0IUAwgc4OQB8CBBPo
7Bg1oG0Bggl0dsoJtC1AMGGDdHb9rnU4tUao9r50aNF0rTuq9Vfb2tpWnKNF1LU26d69e82DBw/s
Ytha59NfyNvh1nLVgtpaMFuLamuvTW1CrPVGfbTYtnamyJIPLcJ97do1m25VVZUZGxvDqAGCCQgm
rJ1gtra2WvFxi1lrce6RkRH72/LyshUiLYbtn6O9MhX25MkTK1hXrlyx36M7RUhIBwcHC7tMKG4t
gC6uXr1qw336+/utSGbJh451O1hoJ42mpiaMGiCYgGDC2gmmRnw+2rU+uo+hdpZIOkff/b0K/bS0
g0R0P0qNTMXs7KwdZbq09PfgwYOFuEP50IjYj1u7YWDUAMEEBBPWTDCjaIQY3TDa3/E+tOmx/90/
z4/fceLECTuKFNq3Uds2Zc1HdM9DiStGDRBMQDBh3QQzTuSyCmT0e9xGvn7406dPTW1trf1fzy5f
vnyZOR+huAEQTEAwYU0FU8LlT7GuRjAVV3RKNrr7RXV1tX0eqenYPPlobGwsintmZgajBggmIJiw
foIpRxznTKOPvsu7tRTB1LkDAwOFuIaGhkxNTU3R8XLkkZer79CTJR+awu3u7i44/TQ3N2PUAMEE
BBPWTzBFR0eH9X7VaFDPFZ0HbV7BFO61En3kITs3N1cU/vXrV5uORC9PPkRvb691ItKrJ/KqxagB
ggkIJtDZAehDgGACnR2APgQIJtDZAehDAAgmnR2APgSAYNLZAYA+BAgmnR0A6EOAYAKdHYA+BAgm
0NkB6EOAYAKdHYA+BAgm0NkB6EMACCadHYA+BIBg0tkB6EMACCadHQDoQ4BgAp0dgD4ECCbQ2QHo
Q4BgAp0dgD4ECCbQ4QHoOwAIJh0fgD4DgGBucgPAhw+fbB8ABBOAkQwAIJgACCYAIJgACCYAIJgA
CCYAIJgAgGACAIIJgGACAIIJgGACAIIJgGACAIIJgGACAIIJgGACAIIJgGACAIIJAAgmACCYAAgm
ACCYAAgmACCYAAgmACCYAAgmACCYAAgmACCYAAgmACCYAHQWBBMAwQQABBMAEEwABBMAEEwABBMA
EEwABBMAEEwABBMAEEwABBMAEEwABBMAEEwAQDABAMEEQDABAMEEQDABAMEEQDABAMEEQDABAMEE
QDABAMEE2AZCGf0AAIIJAAgmACCYAKsXTQBAMAEAwQQABBMAwQQABBMAwQQABBNgo4gmACCYAIBg
AgCCCeUWDj7b5wO0e9o9ggmMsoA65xpA5jqnFQBGA6h7yg4Z6p6WABgNoA1QZsjQBmgNgOEA2gBl
BgQTMBxAG6DMgGAChgNoA5QZEEzAcABtgDIDggkYDqANUGZAMAHDAbQBygwIJtBoYllaWjI1NTWp
xzx8+HBFPN++fTPnzp0zu3fvNhUVFebChQvmy5cvmcMxvJRho7b7mzdvmj179ti229LSYj5//lwU
b/SzY8eOQvj379/NpUuXzK5du8y+fftMW1ub7Qu0GQQTNnnDX15eNufPn089ZmFhwZw8eXLFMV1d
Xaazs9P8+vXLfu7fv286Ojoyh2M4KMNGbPe9vb1mcHCw0G67u7tt+0/iyZMnRe36ypUr5s6dO4Xz
BwYGbFq0GQQTNnnDlyGQIKYdc/r0afP+/fsVx5w6dcrMzMwUGaEzZ85kDo/L5+vXr83+/ftNQ0ND
kfBWVlbaUaru1n1+/vxp7+Y1EqitrTWTk5MrRgo6T+Eq68ePH1PTk4G7du2aHV1UVVWZsbGxonI/
e/bM7Ny5044ojhw5YiYmJjB+W6zdHzp0yPz48aPoN9V5HGovR48etaNKh0aW+t0/Ru2Jdo9gwiY3
HC9fvkw9RnfXutuOO0adyzcM7res4XH5bG1tted8+vTJ/jY8PGxGRkbsbxJcdWTdvTtu375tp4vF
06dPzeHDhwthfX19RSMFxSUjk5Zef3+/6enpsb9p+ripqamo3DIaz58/t/+/ePHCGlcEc+u1e8fi
4qIVrosXL8aGq01FZ02igilx02+0ewQTtoixjDvmzZs3dpSYdEzcXbf/Wyg8Lg/+nbCor69fIbp+
Z5WhiIY76urqrLHyDZeeKaWlpztu/5y3b98WlVt35c5QMb22Ndu9Q8/cNUrT5927d7HHaHQ5Pz9f
9JvESdOwapd6Tnr9+vWiZ5y0ewQTtpjh0BSTOlHU2cEnzgj4ghgKz5JPHZ/mYJEWXyj9pPSiU27+
cbq71ncZND2fRTC3rmA6NL2pacgos7Oz5tixYyt+l4OPxFZtSU5FajOhESbtHsGETWw4Ll++bB49
epR6TNz0anRKNi08Sz7T7sxDhiMurKgDZTAcccfp+Y+mwfRst729HcHc4oKpKdG4dqFRpMQ0hJ7j
67kg7R7BhC1qOLJszqqO4ztHaPrJ9yYMhWfJp+7s9RwpCd3BJ01N6dzo1JR/px+XXmNjY9E5MnZJ
129qamrTCBGCmf0YTT/6rz9FpzQd8nyVgITQjWfSM1DaPYIJW/ROO+61EucooM/du3eLpmtC4Vny
IAcGPw5990VXzg+aLhLj4+MrnB/csyR9hoaGit67i0tvdHTUOjo554fm5uai4xS/PAaFnCDS7vQR
zM3Z7jVq9F+HunXrlv1E0TNF5zTjozbiZmc+fPhgbxz1TJB2j2DCNhZMGQt1LN296nP27NmiF7RD
4VnzIC9ETeUqDi2E4BspjVr1Yrk6sJwdoobJudfrI2eMubm5YHp6D08jCrn0y8PQP07TUkpHU2ZK
0xkRBHPrtHtNwcqLVO1N7SZp2lX1HzfKUxvU83/3DDPkLEO7RzABYwm0AcoMCCZgOIA2QJkBwQQM
B9AGKDMgmICxBNoAZQYEEwDDAbQB2j0gmIDhANoAZQYEEzAcQBugzIBgAoYDaANrUaa0ctHuAcEE
jCXQBowJLt1IuwcEEzCWlLvka5G2RvBW/GyWtva7z0cwARBMKp8RJoJJu0cwYfWdSetBal1IrQ+p
HQ4mJiYKYdq5QGtQ7t6929TW1prJycmi+LS2pHZ10JqZDi22rnUotX5lW1vbivTSwhWndpivrq4u
rFfpdnjPcr7W9Lx27Zpde1NbKWmHeozI9hDMUsqc1Ja0j6UWM/f7yJkzZzL1ibR0/d+ytFXaOoIJ
G8xY+qKknQ/8Hd21G4JbNFpbGPm7ISg+LU6tjusWhNZizRI8/abFq9WJ79y5UzgnFK44tcC02wk+
uiNC6Pz+/v7C7g7abaGpqQkjss1HIEllTmtLas/aFFphWuBcfUIbRWfpE1kFM9RWaesIJmxAw6ER
YtJOCjIGSfvtKT4nbA7txB493hfgUHhcnH6+Q+drpOvv56fdGzAiCGYcobYkwZIoSaSuX7+euU9k
FcxQW6WtI5iwAQ2HRpUKUweN7lOZtt9d0o7t0WdJ/q7xofCQkckSf3TaCiOCYCbNrKS1JSda2urq
69evuftElrac1lZp6wgmbFBjqWeRml7SJrft7e0lC2bU4OQNDxmZ0Plx+cWIIJiltEWhvVs1olwP
waStI5iwyYzl1NRU0XHa+DbL9JNDTkOLi4uJ8YfCQ0YmdH5jY2PRNNXMzAxGBMEsqS0ODQ3ZZ4h3
794tmpLN2iei6c7Pzxf9FmqrtHUEEzag4dAdtNs5PepkIwcHTdkKeQ0mOTg4+vr6Co4I+uj7yZMn
M4eHBDN0/ujoqOnu7i44QjQ3N2NEEMzY39Pakpx+jh8/XiRe79+/z9UnfGe6hYUF68zmh4faKm0d
wYQNaDg0HVtXV1d4jcOJp5CHYEtLi/1dx8ixIBRfR0eHdXXftWuXNRLOgzZLeEgws8Tf29trnzvJ
HV+OGxgRBDOJpLakNu+/VqL/FZ6nT7ibT/UrjUrVr6J5CbVV2jqCCRhLoA1QZkAwAcMBtAHKDAgm
YDiANkCZAcEEDAfQBigzIJgAGA5AMAHB5HIAhgNoA5QZEEzAcABtgDIDggkYDqANUGZAMAHDAbQB
ygwIJmA4gDZAmQHBBAwH0AYoMyCYQKMB2gBlBgQTAMMBtAHaPSCYgOEA2gBlBgQTMBxAG6DMgGAC
hgNoA5QZEEzAeAB1T9lhw9c9LQEwHkCdcw0gQ53TCqCkhsRn+3yAdk+7RzABGGUAQHYbwCUAQDAB
AMEEQDABAMEEQDABAMEEQDABAMEEQDABAMEEQDABAMEEQDABAMEEAAQTABBMAAQTABBMAAQTABBM
AAQTABBMAAQTABBMAAQTABBMAAQTABBMAEAwAQDBBEAwAQDBBEAwAQDBBEAwAQDBBEAwAQDBBEAw
AQDBBEAwAQDBBKCzIJgACCYAIJgAgGACIJgAgGACIJgAgGACIJgAgGACIJgAgGACIJgAgGACIJgA
gGACAIIJAAgmAIIJAAgmAIIJAAgmAIIJAAgmAIIJAAgmAIIJAAgmAIIJAAgmACCYAIBgAiCYAIBg
AiCYAIBgAiCYsO71z2f7fBBMAAQTqHsosc5pBQAYTaDeIUPd0xIAMJxAnUOGNkBrAMB4AnUOCCYA
xhOoc0AwATCeQJ0DggmA8QTqHBBMAIwnUOeAYAJgPIE63yhMT09vqHjWOk4EEwDjCRuwzpeWlkxN
TU1s2NjYmDl48KDZtWuXOXbsmJmamkqM59mzZ2bnzp2mvr4+vxEP5FHpl4NyxZMWZ9Y+tp59EcEE
QDBhlXW+vLxszp8/H3vMmzdvTGNjo5mfnze/fv0yo6Oj5vDhw4lxSSyfP39emhEPtMtytdu1aP+l
xolgAiCYsInq/OTJk2ZhYSH2mIsXL5re3t7MaUTXMI1dli1BJNPymLQ+aldXl6msrDQVFRWmra2t
8PuFCxfM+Ph40cj3zJkzmdZZ/fDhgzl37pzZvXu3vQGora01jx8/LsrL69evzf79+01DQ0Ow3D9/
/jSXLl2y8SmuycnJxDInlccfve/YscMcOXLETExMIJgACCasZ52/fPky8Zjq6upcz+dWLMFWJsGM
Cx8eHjYjIyN25KtRsqaO79y5Y8M+ffpkp48VpunmQ4cOmdnZ2UzpHD161I6kda4+g4ODVhz9fLS2
ttowpRMq9+3bt83Dhw/t/0+fPi0aofvHpZUnOnp/8eKFLROCCYBgwm+o87hjZKRlnDUy0gippaXF
fPv2bUMIpp6TSlx8fBGRAPX391vRuX79+qrav0Z1/vkfP37MXG4JZDSfcceFyiPRdsK72jaABQBA
MKHMgqnfrl69ahYXF60xlwhpmnYjCKbEPDod6gubE6F9+/aZr1+/5roWmnLVyFBlraurC+YzrdzK
Z5YyhcqjGxf9pjJ1dnYimAAIJmwkwdyzZ499BueQaKZ5mZZDMJOeM0bjiopjHGfPnrUjvDyCee/e
PXvO3bt37XS1pl3XQzCzlEdCrmnd06dPm/b2dgQTAMGEjSKYcpTxkWBqarZUwZS3bblGmHJ80cg3
iaGhIftMUMKXZ0pWNwl+vGl5zlJuva6TZUo2VB4fvdqTtx8jmAAIJqyhYOqZmT7OAWZgYMA602SN
w3dUkSeuvE9LFUwJtZ4duhFvX1+f6enpKeRN3+XxKzQqPH78eJEYvX//PjaeKHJ0cl6xMzMztryh
fEbjjDr9aDpVyHM3yeknrTxC58lTVuiapo1cEUwABBPWWTCFRFIOJ5qKleA54ckShzPsmm7USEsG
v1TBlPOO8uBPCXd0dNgRocub81qVc5L/Won+V3hSPD6vXr2yzjbKt0RKNwyhfEbj9I+Rl67yo/j0
PPTt27eJcSWVR2g6VufrWiouJ54IJgCCCdQ5rFEboDUAYDyBOgcEEwDjCdQ5IJgAGE+gzgHBBMB4
AnUOCCYAxhOoc0AwATCeQJ0DgglAxwHqHBBMAMB4AnUOCCYAxhM2bJ2vNq3ffT6CCQAYFOocwaQN
IJgAGBQotc67urpMZWWlqaioMG1tbYXfL1y4ULQeq9YudbuXaJHxS5cu2UXHtbn05ORkvGEO7Oyh
RcavXbtm10+tqqoyY2NjK85Jyl+W82nrCCYAggllqXNtCK0tsCQ8y8vLVnC0kLjQwt/aqUNhWkBc
C5LPzs7aMO3AoUXJhfZnTNqBIySY/f39hR06vnz5YpqamorC0/KX5XxAMAEQTChLndfX16/Yq1HC
6AuWREki5e8pKYHMssdjSDAbGhqKttnSTh5+eCh/ofMBwQRAMKEsda5tohTmf7R9VFRU9+3bZ75+
/Vp0XibDHBDMaDwSx2h4Wv5C5wOCCYBgQlnqPCqOcZw9e9aOKNdDMKPhofyFzgcEEwDBhLLU+ZEj
R8zi4mLieUNDQ/YZ4t27d4umZLUZdClTsvPz80W/NTY2Fk2pzszMFIWH8hc6HxBMAAQTylLnfX19
BacZffT95MmTNkxOP8ePHy8Sr/fv39v/5fTz4sUL+788aZOcfjQCfP78uf1/YWHBnDt3rih8dHTU
dHd3F5x2mpubi8LT8pflfEAwARBMKFudd3R02Ncydu3aZQVNQilaWlqKXivR/woX8ppVuASxrq7O
OtvEpSWx1DGaWtWoVK+mRPPS29trn5Hq1RE5GUXDk/KX5XzaOoIJgGACdQ4IJgDGE6hzQDABMJ5A
nQOCCYDxBOocEEwAjCdQ54BgAmA8gToHBBMAMJ7UOReBNoBgAmA8gToHBBMA4wnUOSCYABhPoM4B
wQTAeAJ1DggmAMYTqHNAMAEwnkCdA4IJABhP6hwQTADAeAJ1DggmAMYTqHNAMAEwnkCdA4IJgPEE
6hwQTACMJ1DnZWd6enrTxr/WeUcwATCesM51rt+jnx07dvy29uYfu2vXrjW9JtH4y9kv1jrvCCYA
ggm/uc6fPHliOjo6NoRgrnU7Xcv4N2IfQzABEEwoU53/+vXLHD161Hz//j3xmA8fPphz586Z3bt3
m507d5ra2lrz+PHjojiuXbtm9uzZY6qqqszY2FhQBOPCo6PepDLdu3fP7Nu3z1RUVJjW1laztLSU
Ka9x8UfT6erqMpWVlTbutra2FWmPjIyY6upqOyJX/M+fP0+M+9mzZ/YYHXvkyBEzMTGBYAIgmLBZ
63x4eDg4upSgjo6OWmHUZ3Bw0Ozfv78Q3t/fb3p6emzYly9fTFNTU0mCmSXPCq+vrzcfP3606Ung
rl+/njmv0fj977oWEkSdt7y8bIX/zp07RcdKjJW2kFhKEJPi9gX1xYsX5tChQwgmAIIJm7XOJTDz
8/O54/afeTY0NJifP38Wvr99+3ZNBXNycrLw/cePH+bAgQOZ85ommBJiiaWPL3I61olllrxLqB8+
fLhh2gAWAADBhBLrfHZ21hw7dixTXK9fvza3b982Fy9eNHV1dUVx+6MsIdFZS8GMilo0/bS8pgmm
4klzhspTDjeqdCPizs5OBBMAwYTNWucDAwPm5s2bwXj0zPDw4cPm7t275uXLl+bTp0+pgplFBFcj
mFH89EN5TRPMkKdwXsF04v306VNz+vRp097ejmACIJiwGev8/Pnz1piHkDPP4uJi4bumcP24Gxsb
i6ZkZ2ZmUoUken5ewZyamip8//btm81f1rymCaYcc/xzyyGYDuX5d/RBBBMAwYQy1Lmez2kEFkJe
oc7TVGKoaVw/bjnZdHd3F5x+mpubV4xAnfPLwsKCdZxJEhp5t+o5oS/A0TKdPHnSpqP0bt26ZYU/
a16j8fthfX19BeclffRdaWUVzGjcGunKU1ZEHYQQTAAEEzZRncuAR58HxvHq1SsrrjpeIiBHlmjc
vb299lUPvZIhb1M/3ImFpjxramqsiCQJprxStQBA0iIAOlaC+Mcff1inmhs3bthRZta8RuOPlkMe
wxqlKlzC7t9QhAQzGremY/UM1b2C4sQTwQRAMIE6p0wb+Hpx5QAwNIBgAoIJgKEB6txnI67XimAC
YDyBOgcEEwDjCdQ5IJgAgPEE6hwQTACMJ1DngGACYDyBOgcEEwDjCdQ5IJgAGE/YJnVOW0IwATCe
QJ3TlhBMADoO3YU6//9oW6+Kigq7YLgWGPc3RtZ5IyMjdiFztw6qWzzdhc/NzdnNp6MsLy/bDZ2/
f/9OBSCYAAgmbO461y4cg4ODhV05tFj6pUuXis7TwuNORKM7bbh4tSvJxMREUdwS2itXrnDxEUwA
BBM2f51rBw1/+yz9r51G/PP8EecKw/v//ncbI/s0NDSYd+/ecfERTAAEEzZ/nWuaNUrcCDIkmELT
trOzs/b/t2/fWsEEBBMAwYQtUedxGxknCWIoXBtHX7161f6vad2///6bC49gAiCYsDXq/MiRIyum
ZP1dQPII5pcvX6zj0OfPn+3m0UtLS1x4BBMAwYStUedy+hkYGCg4/QwNDZmampqSBNONLP/880/T
2trKRUcwARBM2Fp17l4r0UeCp9dEShXMyclJ+9v09DQXHcEEQDCBOk/i06dP1vkHEEwAjCdQ5wlo
Srejo8N0dnZywRFMAIwnUOdJyOHn1KlTOPsgmAAYT6DOAcEEwHgCdQ4IJgBgPKlz6pw2gGACYDyB
OgcEEwDjCdQ5IJgAGE+gzgHBBMB4AnUOCCYAxhOoc0AwATCeQJ0DggkAGE/qHBBMAMB4AnUOCCYA
xhOoc0AwATCeQJ0DggmA8QTqHBBMAIwnUOeAYAJgPIE635JMT08jmACA8YTsdX7z5k2zZ88euwF0
S0uL+fz587a4Jrt27dpW/QLBBEAwYRV13tvbawYHB82vX7/sp7u725w8eZJ+gGACAIJJnfscOnTI
/Pjxo+i3nTt3psZz7949s2/fPlNRUWFaW1vN0tJSUfjr16/N/v37TUNDQ9EoVsdrFCtB/vjxYyHs
2bNnNs0dO3aYI0eOmImJiczpia6uLlNZWWnD29raisJ+/vxpLl26ZNOtra01k5OThXj9j/vt+/fv
5sCBAyvSUDzKW5Y0EUwABBO2eJ0vLi5aIbh48WJqPPX19VbwNCLV8devXy8Kl6gp7NOnT/a3vr6+
olHs8PCwFTFfoJ8/f27/f/HihRXxrOkprpGRERu2vLxsxsbGzJ07dwrht2/fNg8fPrT/P3361Bw+
fDjxmrjvV69etXn26e/vt2lnSRPBBEAwYQvX+YULF+xoSZ93796lxuNGaUKjU43I/HB/9Cjq6urs
CM0frWnE6NBo1Ila3vQkphKu6KjZIYGMhocEc3Z21qbhztPfgwcPFsoVShPBBEAwYRvUuaZO/anH
uHiiYuFP4calo6nWKP45GlW6kWRnZ2eu9PR/dHrVTy80vZz0/cSJE3YUKUZHR825c+cyp4lgAiCY
sA3qXFOMeUQmi2DGxRc9Ts89NWV6+vRp097enjm+kFCVKpjKi555Ct1AvHz5MnOaCCYAgglbsM41
Hfrly5fC9+h0aVw8U1NThe/fvn2zr6SkpSPBiU7JRl/pcCjuIsMeSE9x69lrEjU1NbmnZB3V1dX2
2aWmY6PlSUsTwQRAMGEL1rmmYDUN6hxybt26ZT9p8cjLVSLrjj9//nxqOnKgGRgYKKQxNDRkhcyh
54zylBVy/omOWNPSU9w9PT2FuPXdfy1GTj+a8hXj4+NFTj/ynNVzSSfm0bzLkaeqqmqFQ08oTQQT
AMGELVjnmoKVV6tGfHL4kYCG4nn8+LH5448/7Oj0xo0bdtSXRZidU5E8ZOfm5gphmo6VY5CmOiWW
TjyzpCc6OjrsqFNl0LNG550r9HqIFmNQvErj7du3RYKoc9xoN5r3r1+/2jB/BJ4lTQQTAMEE6nzd
2w5tFcEEQDABwaStIpgACCZs1TpPctZZK9Y7PQQTABBM6pyLQBtAMAEwnkCdA4IJgPEE6hwQTACM
J1DngGACYDyBOgcEEwDjCdR5+Zmenv4t5yKYAIBgwprV+VrEuZrXSMrxCkp0HVsEEwDjyUWgzrdc
nOXIz1buGwgmAEYBVlHnWnhca7tqIXJtZ+Vv1izcGrAK1wLj/ubQilOLqmtXD7cOrBZPz3O+1pHV
GrENDQ0r9piMQ+vMKh2lp11DJiYmCnFFz42Lw/9NC6dfu3bNrgmrRdbHxsZSR5hdXV2msrLSlqet
rS1TvhBMAAQTtkidazePhw8f2v+1B6S/m4d24RgcHCzsyjE8PGzF1Y/z7NmzBRGM7jSS5Xwt/K4w
t3h5qG36oqxdSA4dOpRYxpBgausut+uIFlhvampKFEzlXRtK61gtWC9x9XcxScsXggmAYMIWqHMJ
ZNJ+kdrdI7qPpb9XpuL0R4zRdFZ7fhwajTqBD5UxJJga1fr5004mSYJZX1+/4jr5opiWLwQTAMGE
LVDn/ogwiqYX044PCdJqz49DozcdIwHTPp6rEcxo2SWISYKpY6PTvn750vKFYAIgmLDFBTMuLORF
miZIec9PQs89NX18+vRp097eXjbBTMtfnPhnzReCCYBgwhao85qamsQpWTmvRKdU/Vc3QoK02vND
TE1NpQpw9Pv8/HzRb42NjUX5m5mZSYxPZVlcXCwpXwgmAIIJW6DO5fSj6UQxPj6+wulHXrDOaWdo
aMgKbFbBK+V8edPquaYvZD7KnzxSRdTJKHqu74izsLBgzp07V5Tm6Oio6e7uLjj9NDc3JwqmyuIc
hPTRd3n9ZskXggmAYMIWqPOlpSXT0tJiDbycdOT44uNeC9FHHq5zc3O5Roh5z5fnqUahSYsQaNpT
+XSvsTiRijvXCZeOlVDr2Giavb291hFJr4vIEzZtxNrR0WFfQVH8El/n2RvKF4IJgGACdQ6btA3Q
GgAwnkCdA4IJgPEE6hwQTACMJ1DngGACYDyBOgcEEwDjCdQ5IJgAGE+gzgHBBKDjAHUOCCYAYDyB
OgcEEwDjCdQ5IJgAGE+gzgHBBMB4AnUOCCYAxhOoc0AwATCeQJ0DggmA8QTqHBBMAMB4UudcBNoA
ggmA8QTqHBBMAIwnUOeAYAJgPGHr1/n09PSmvW6bOe8IJgCCCWWs88XFRRsW/ZSTXbt2bdrrFs37
Zu47CCYAggmrqPOnT5+alpYW2ts26CsIJgCCCauo8+7ubjMwMJArntevX5v9+/ebhoaGwu9dXV2m
srLSVFRUmLa2tqLjoyPXpDhu3rxpz9+9e7c5efKk+fjxYyHs2bNnZufOnWbHjh3myJEjZmJioiiN
e/fumX379tnzW1tbzdLSUlG+k/Infv78aS5dumTTra2tNZOTk6l5//79uzlw4MCKNBSP8pYlTQQT
AMGETVbn58+fN6dOnbKGfc+ePVa0QvFIkH79+mU+ffpkfxseHjYjIyP2t+XlZTM2Nmbu3LmTmHZc
HH19fWZwcND+po/ilIg5JJbPnz+3/7948cIcOnSoKL76+norsDpXQnX9+vVCeCh/t2/fNg8fPiyM
uA8fPpyad3H16lWbZ5/+/n6bdpY0EUwABBM2WZ3/8ccf5v79+/Z/Gfe///7bCkhaPP7IT0isdK5P
VNBCcdTV1dkRmj9a04jRodGoE7W4PLlRofjx44cdAWbNnwQyGh4SzNnZWZuGO09/Dx48WChXKE0E
EwDBhE1e5zLyEtE88Wj0F52+1NRpSHR8/OP9eB0aVbqRZGdn54r4ouLknxvKn39sVsEUJ06csKNI
MTo6as6dO5c5TQQTAMGELVDnaYY9q9hlFZ000Yoep+eemjI9ffq0aW9vzxxfKH+lCqbyomeeQs8u
X758mTlNBBMAwYRNVuea9pQTi0NToU4EssYjsdDrKasRTMURnZJNeh1lamqq2Pj/73/95vj27Zt9
Hps1fzU1NbmnZB3V1dX22aWmY/NcEwQTAMGETVbnN27csI4qztlGjilDQ0O54pHzS09PTyEOfZeX
q0Pep3q25wQxKQ5567o4lAcJmUPPGeUpK+T8448KFZ/S+/Lliz331q1b1pkpa/70zFZTvmJ8fLzI
6SeUd12vqqqqFQ49oTQRTAAEEzZZnevViCtXrtjR3N69e62RLyWejo4OO6pTPHqW57xfnajodzdi
TIrDvVaijzxk5+bmCmGajpVjkKY6JZZOPF18jx8/ts9e5RykmwCNMrPmT9dA76IqXqXx9u3bzHn/
+vWrDZNY57kmCCYAggnUOWXbBNeJKwaAgQEEExBMAAwMUOdxbOa1ahFMAIwnUOeAYAJgPIE6BwQT
AOMJ1DkgmACA8aTOgTaAYAJgPIE6BwQTAOMJ26HOp6enf8u5CCYAIJiwZnW+FnGu5hWRcrxeEl2j
FsEEwHhyEajzLRdnOfKzXRZ4wAIAYBQgZ51rUXGt26pFxrVLib8Rs3Druypci4f7Gz8rTi2Yrh07
3BqvWhg9z/laI1brvzY0NKzYPzIOrSGrdJSedgSZmJgoxBU9Ny4O/zctin7t2jW73qsWUB8bG0sd
YWqR+srKSluetra2TPlCMAEQTNgida6dOh4+fGj/1/6O/k4d2mFjcHCwsOPG8PCwFVc/zrNnzxZE
MLqLSJbzW1tbbZhbmDzUNn1R1g4jhw4dSixjSDC1LZfbUUSLpzc1NSUKpvKuzaJ17PLyshVXf4eS
tHwhmAAIJmyBOpdAJu0FqZ07ontUav9MP05/xBhNZ7Xnx6HRqBP4UBlDgqlRrZ8/7VKSJJj19fUr
rpMvimn5QjABEEzYAnXujwijaHox7fiQIK32/Dg0etMxErDOzs5VCWa07BLEJMHUsdFpX798aflC
MAEQTNjighkXFvIiTROkvOcnoeeemj4+ffq0aW9vL5tgpuUvTvyz5gvBBEAwYQvUeU1NTeKUrJxX
olOq/qsbIUFa7fkhpqamUgU4+n1+fr7ot8bGxqL8zczMJMansiwuLpaULwQTAMGELVDncvrRdKIY
Hx9f4fQjL1jntDM0NGQFNqvglXK+vGn1XNMXMh/lTx6pIupkFD3Xd8RZWFgw586dK0pzdHTUdHd3
F5x+mpubEwVTZXEOQvrou7x+s+QLwQRAMGEL1PnS0pJpaWmxBl5OOnJ88XGvhegjD9e5ublcI8S8
58vzVKPQpEUINO2pfLrXWJxIxZ3rhEvHSqh1bDTN3t5e64ik10XkCZs2Yu3o6LCvoCh+ia/z7A3l
C8EEQDCBOodN2gZoDQAYT6DOAcEEwHgCdQ4IJgDGE6hzQDABMJ5AnQOCCYDxBOocEEwAjCdQ54Bg
AtBxgDoHBBMAMJ5AnQOCCYDxBOocEEwAjCdQ54BgAmA8gToHBBMA4wnUOSCYABhPoM4BwQTAeAJ1
DggmAGA8qXMuAm0AwQTAeAJ1DggmAMYTqHNAMAEwnkCdA4IJgPGETVPnS0tLpqamZlO0s7zxlisf
m73fIJgACCasss6Xl5fN+fPnN027+F2CyQgTAOMJ27zOT548aRYWFjK1Cx1z9+5ds2/fPrN3717z
4MED09fXZ/bs2WN27txpnj9/viLNCxcumPHx8cLvz549M2fOnCl87+rqMpWVlaaiosK0tbUVpffr
1y9z7do1G39VVZUZGxtLzWeW49PSU95Ujh07dpgjR46YiYmJxGuoeJSOrsPg4GCxIP3v/5GREVNd
XW3jil4bBBMAwYRNWOcvX77M3C50zOXLl+2o9MmTJ1Ywrly5Yr9LECQM0TQ/ffpkjh07ZsVMU7+H
Dh0ys7OzNmx4eNgKi8IUhwTuzp07hTj6+/tNT0+PDf/y5YtpampKzWfo+FB6vrC9ePHC5jXuGiqO
9vb2QjrHjx9fIZjnzp0zHz9+tN+j1wbBBEAwYRPXedZjnAi474uLi/FGOSJUEjOJ0/Xr1wu/19fX
W9Hx8UWqoaHB/Pz5s/D97du3qfkMHR9Kb//+/ebhw4fB69PY2Gg+f/6cmE70Om2EfodgAiCYsM6C
mfV7NExipancr1+/Fo3odJz/0RSmH+4jsUvLZ+j4UHoaVeo35bWzszOxbLt27UpNJy6PCCYAggkI
ZibBPHv2rDl8+HCRYPpilUUAQ/kMHR9KT7x+/do8ffrUnD592k67xsUTEmYEEwDBBASzJMEcGhqy
z/3kMORPycqxxp/SjaKpT3+KdWZmJjWfoeND6flMTU0llkfPZPXs0vHu3TsEEwDBBARzdYIppx85
xfii9f79e/u/PGydk44++i6vXcfo6Kjp7u4uONc0Nzen5jN0fCg9jYDlKSuSnJhE1OlHcSCYAAgm
IJirEsyWlpai10r0vzxIHR0dHdbbVs8F9bsE1qe3t9c++9SrIHIeCuUzdHxaepqOraurK7wK4sQz
rqwSZqWh11eUjv9cE8EEQDCBOocY9LrMgQMHNk0boDUAYDyBOl8XNIKVY5B7n/PmzZtFDkIIJgDG
E6hzMP93sQe986lpWK30c+PGDSucCCYAxhOoc9hCbYDWAIDxBOocEEwAjCdQ54BgAmA8gToHBBMA
4wnUOSCYABhPoM4BwQTAeAJ1DggmAB0HqHNAMAEA4wnUOSCYABhPoM4BwQTAeAJ1DggmAMYTqHNA
MAEwnkCdA4IJgPEE6hwQTACMJ1DngGACAMaTOt/weZyent5Q8ax1nAgmAMYTNmmdP3z4MHjcs2fP
zM6dO019fX1+Ix2IW5sxl4NyxZMWZ9Y+tJH6GoIJgGBCGep8YWHBnDx5MnicxPL58+elGelA3OVq
l2vRvkuNE8EEQDBhi9X56dOnzfv371OPU5j/SYo3SSTzxi26urpMZWWlqaioMG1tbYXfL1y4YMbH
x4tGvmfOnEmMx+fDhw/m3LlzZvfu3fYGoLa21jx+/LgoL69fvzb79+83DQ0NwXL//PnTXLp0ycan
uCYnJxPLnFQef/S+Y8cOc+TIETMxMYFgAiCYsJHqvLu72wwODpY0CiyXYMaFDw8Pm5GREfPr1y+z
vLxsxsbGzJ07d2zYp0+fzLFjx2zY0tKSOXTokJmdnc2UztGjR83o6Kg9Vx+VXeLo56O1tdWGKZ1Q
uW/fvm2ns8XTp0/N4cOHY49LK0909P7ixQtbJgQTAMGEDVLnb968MadOnSpZ1NZSMPWcVOLi44uI
BKi/v9+KzvXr11fVvjWq88//+PFj5nJLIKP5jDsuVB6JthPetW4DWAAABBNy1Pn379/tlOPnz583
pGBqxBWdDvWFzYnQvn37zNevX3O1b025amR48eJFU1dXF8xnWrmVzyxlCpVHo0r9pjJ1dnYimAAI
JmyUOr98+bJ59OhRrrZRDsFMes4YjSsqjnGcPXvWjvDyCOa9e/fsOXfv3jUvX760067rIZhZyiMh
17Sunim3t7cjmAAIJmyEOo8KV8hZJotgzs/Pl22EKceXxcXFxOOHhobsM0EJX54p2T179hTFm5bn
LOWuqanJNCUbKo/P1NRU2fspggmAYEIZ67yUaVPnqKJXU+R9WqpgystUzw7ldSr6+vpMT09PwTlH
3/Xqi9Co8Pjx40ViJC/fuHiiVFdXF7xiZ2ZmrPNQKJ/ROKNOP5pOFfLcTXL6SSuP0HnylBW6pmkj
VwQTAMGETSaYzrBrulEjLRn8UgVTzjtaIMBfJKCjo8OOCPWbxNh5rba0tBS9VqL/FZ4Uj8+rV6+s
s43yLZGKLtgQl89onP4x8tJVfhSfnoe+ffs2Ma6k8ghNx+p8XUvF5cQTwQRAMIE6h9/UBmgNABhP
oM4BwQTAeAJ1DggmAMYTqHNAMAEwnkCdA4IJgPEE6hwQTACMJ1DngGAC0HGAOgcEEwAwnkCdr4bp
6WkEEwDjSXehzrdG+1jLvCatFIRgAmA8gTpHMLdwP0EwATAEsIo61yLg165ds+ubVlVVmbGxsRXH
dnV1mcrKSlNRUWHa2tpWxJEWrri0m4j2rNy7d6958OCBXXRc6fkLt2eJK0teo2lrNxMttu7WZ42m
d/PmTZuWFlfXQuhu4+isu7cgmAAIJmyTOu/v7y/soPHlyxfT1NRUdOzw8LAVHYUvLy9bkdJC5FnD
FZf23VTYkydPrNhduXLFfo/uyBGKK5TXuDJrgXMngtH0JNyDg4OF3UOU/qVLlxhhAgCCSZ2vpKGh
oWgbLO204R9bX1+/Yq9H7fSRNVxxOcFy3/09IfOkFcprXJn9tKPpaWcQPz79r5EwggkACCZ1voLo
nosSLP9YhUenJzW9mTU8tOF03rTS8pqlzP5vftxxaSCYAIBgUueJIpRFVHxC4XkEMxRXKK95BTMU
H4IJAAgmdV6gsbGxaFpyZmam6NgjR44UTaFGCYXnEcxQXKG85hVMpRedkvVfJUEwAQDBpM4LjI6O
mu7u7oIjTXNzc9Gxcoxxjjb66Lu8SbOG5xHMUFyhvOYVTMU/MDBQSG9oaMjU1NQUwuU5q2egvqgi
mAAYT9jGdd7b22udXfQ6hzxFo8d2dHRY71aNvuR1+unTp8zheQQzS1qhvOYRTOFeK9FHHrJzc3OF
MHnoKh9bZQEDBBMAwQTqHBBMAIwnUOeAYAJgPIE6BwQTAOMJ1DkgmAAYT6DOAcEEwHgCdQ4IJgBg
PKlzQDC5HAAYT6DOAcEEwHgCde4xPT1NxSKYABhP2Lh1vlHaz1ZZgQfBBEAwAcGkHSOYAJu3w0Q/
sL0FU7+/fv3a7N+/327Q7Ojq6rLrtWqN1ba2ttS44o79/v27OXDggFlaWio6VguZa5cQ8eHDB7te
rBY511ZbtbW15vHjx0XpjIyMmOrqarv1l455/vx5bFtGQBFMAAQT1lwwW1tb7W4dbqFzLWouodJv
y8vLZmxszC5EHhdX2rFXr161O4L49Pf3W4EVR48etTuQuN1CBgcHrXD76UhQtWOIkFhu5Q2eEUyA
DSyagGDqdydIjvr6eitgPocOHYqNK+3Y2dlZO8p04fp78ODBFen5+JtIx+VtK2/wjGACIJiwwQUz
ikZx0ZmIqJBlPfbEiRN2BCo0mtSI0UfTwbdv3zYXL140dXV1QUFEMBFMAAQTNoxg+oIXOid07NOn
T+2zSaFnly9fviyE3bt3zxw+fNjcvXvX/q4pYQQTwQRAMGHTCKaEbXFxMVNcoWOFnHb07FLTsT7a
KNo/d35+HsFEMAE2h/EEBFPIUaenp6fgjKPvJ0+ejD0ndKyQE1BVVVWR45ATUucVOzMzY44dO5ZL
MOVdq2ec8rwFBBMAwYR1F0zR0dFhR4BaHEDPHZ0Hbdw5aceKr1+/2rAvX74U/f7q1SvrIKTnoJqa
ffjwYS7BlAArXreAAe0awYQ1bkB8ts8HYwm0AQQTMCBAnVN2QDAB4wHUPeUGBBMwHEAboMyAYAKG
A2gDlBkQTMBwAG2AMgOCCRgOoA1QZkAwgUYDtAHKDAgmAIYDaAOUGRBMwHD8j+np6Q0Vz1rHSRug
zIBgwgYyHD9+/LAb3mrXeC211dLSYr59+7biOO0gX1NTE0zn2bNndskv7ReYuzEHjJtbCmy1lCue
tDizGur1NOgIJiCYAKswHNevXzdDQ0OFRaRv3rxpRdNHO8qfP38+k/GRWGqH+JIacyD+chm/tTCi
pcaJYFJmQDBhkxiOvXv3Fu0cL3GMjpa0C8PCwkImQYuuYZpnq6K0+JPWR+3q6jKVlZV2hNzW1lb4
/cKFC2Z8fLxo5HvmzJlM66x++PDBLqatXSF0A6B9Dd3uEi4v2gB4//79pqGhIVhu7Spx6dIlG5/i
mpycTCxzUnn80bv2YtT2UhMTE4gHZQYEE36X4ZBxlxD4uM1vs8QRPaZcghkXPjw8bHe1l+BL6MfG
xgpbKWnnCG2bpDBNJ2t3iNnZ2UzpHD161IyOjhZG3YODg0XXROe3trbaMLdDRVq5b9++bXekENpY
WDtUxB2XVp7o6P3Fixe2TIgHZQYEE36T4bh//7418KXGsZ6Cqeek/uhY+CIiAdIGvhIdTT2vxohq
VOefr/0Is5ZbAhnNZ9xxofJItJ3wIh6UGRBM+I2GQ/v3aSpTo5vNIJgacUWnQ31hcyK0b98+W7Y8
5dCUq24cLl68aOrq6nLtVxj9rnxmKVOoPBpV6jeVqbOzE/GgzIBgwu8wHBLJv/76a8Vmt79DMJOe
M0bjiopjHGfPnrUjvDyCee/ePXvO3bt37XS0pl3XQzCzlEdCrmnd06dPm/b2dsSDMgOCCetpOCQm
erVkfn5+1cYnJJhKo1wjTDm+LC4uJh4v7189E5Tw5ZmS3bNnT1G8aXnOUm69jpNlSjZUHp+pqanc
YoBgAoIJsArD8c8//5gTJ06Yz58/l8X4xE2bOkcVedrK+7RUwZSXqZ4dyjFJ9PX1mZ6enoJzjr7L
o1doVHj8+PEiMXr//n1sPFGqq6sLXrEzMzPWeSiUz2icUacfTacKee4mOf2klUfoPHnKCl3TtJEr
4rFxy7wZFrlAMIFGE8OBAwdWTIEmHVuKYDrDrulGjbRk8EsVTDnv6JUX/7WXjo4OOyLUbxJj57Wq
d0n910r0v8KT4vF59eqVdbZRviVScrQJ5TMap3+MvHSVH8Wn56Fv375NjCupPELTsTpf11JxOfFE
MEsrs9451rXWzY7qJ8tNY8mG2vu/HAtn5KnL7T7KRjBhS9xpA23gd5W5t7fXvi7kRvPd3d1Fo/m1
THu96wHBRDCBTgO0gZLLrBkELQvpE5riTltUQqJ77do1O2Ktqqqy79DmcWjTaFfxarQr4fZfW4ou
lBEtV5aFNhyrXfwCwQSMJdAGtnGZ5WglMdQrREmEFpXQ+77u+bM8zZuamjI/etCzan+0q7S0MpR/
fNpCGVkW2vBvClaz+AWCCRgOoA1s0zLrvWON7PR59+5d4nGhRSU08vOdyPScOqtg6rm0f67+17vD
/vGhhTKiRBfacKx28QsEEzAcQBvY5mXWlKimKJMILSoRnc6VuGYVzLj3b/34srzGlHWhjdUufoFg
AoYDaAPbvMyaZk17hhlaVCLu3KyCmefcuN/yLrSxmsUvEEzAcABtYJuVWVOT/qpW0WnQKKFFJRob
G4umVfX+blbBVNzRKVn/1ZOQYJay0IYoZfELBBMwlkAb2GZl1hSspiSdo8ytW7fsJ4nQohJyutGr
Kc7pp7m5OVG04hbgGBgYKMStFar8zdpDgplnoY3VLn6BYALGEmgD26zMmoKV56lGcnL4kYCGSFtU
QujdTo1S9eqJPF2TRCtu4Qz3Wok+8pCdm5vLLJh5FtpY7eIXCCZgLLdx2d17aXKCoA1QZkAwARDM
BPz30mgDlBkQTIBEwxFaJSRtZZDQqiFpK6OsVbyhFVei16Qcq64gHpQZEEzYBoYjtEpI2sogaWGh
lVHWKt7Qiiuh61LKqiuIB2UGBBO2qeHw3zlLWxkkLSy0MspaxRtacSV0XUpZdQXxoMyAYMI2MRxp
q4SkrQySFhZaGWWt4g2tuBK6LqWsuoJ4UGZAMGEbGI7QKiFOUJNWBkkKC62MslbxhlZNCYWVsuoK
4kGZAcGEbWA4QquE+KStDBINC62MslbxhlZcCV2XUlZdQTx+b5ny1C8gmAAlG8vQKiFpK4OkhYVW
RlmreEMrroSuSymrriCYv18wkzyeEUxAMKFsxjK0SkjayiChVUPSVkZZq3hF2oorWa5L3lVXNlsb
SBKZrfoBbB+CCdt+dAG0AUaYgGACxhJoAzkEk3YPCCZgLIE2QJkBwQQMB9AGKDMgmIDhANoAZQYE
EzAcQBugzIBgAoYDaAOUGRBMoNEAbYAyA4IJsGUNx/T0NJWIeFBmQDBh4xqOUl8Cz3Ne0rH+//56
roB4lKvMS0tLRUsfUhcIJkBZBHM90k46FgODkS53mbUB+fnz52lbCCZAdsPR1dVl113V2qltbW2Z
R4o6T2u67t271wwODqaOFLXpstZl3b17tzlz5ozd2DnrCDO67NnRo0djjd+BAwfM9+/fqWwEM1OZ
tWj/wsJCpuuiY7TGsTY31yblaX1HbVBtUaNXH+18o91wkvpSXB88ePCg+fr1q/3f7ST05s0b+/3z
5882HBBMWCfDocXJR0ZG7M4cEp2xsTFz586doJjpHO1T6XYFOX78eKrwadstdXAd/+jRI3P58uXM
ghn9XzuQTExMFJVD+bly5QoVjWBmLrP2f816XXRMa2urbb9usf+0vnP16lW7841Pf3+/FcZommnx
/PXXX7a/iAcPHthHEzrefddNKCCYsE6Go76+3nZUH+1eEhItJ4AOjRjTxM4fUSo9pVuqYLqNpX10
1//u3TsqGsHMXeasx2iWJGvfmZ2dtaNMF66/Gg26OPw00+LRBu8SX/Hf//7XXLx40X6EbjolroBg
wjoZDm2fFZ3y1LZaIdGKOuGow2cROz/dUgVTaB9PGSUn1v40GSCYayGYefvOiRMn7MhRaJ9WbUUX
F19aPGrj7hGEpnO1obqEWNTW1tppWkAwYZ0Mh9/Bg40t0slXI5i+4JYimNok2t15a1rq77//ppIR
zHUVzFDf0UyIRM2JnZsCjsYXikc+Anrs4YRSN4va7N19BwQT1slwqCMvLi7mFsxjx47ZTuzQdGia
2LnRoJDzg9/ZSxFMpS0HIk0Ly1ki6mABCOZaC2ao7zhx07PLqHOOH18oHnny/uc//ylMxbppWfcd
EExYJ8Mhx4Senh47QtRH3+U9GBKtqNOPzkkTu1OnTllvPx2v9PI6/Ugc9fxHYuvQyPLPP/+0zhiA
YK63YIb6jpDzTlVVVZEjXTS+UDwDAwNm3759ZmhoyH7XbIr6g5vuBQQT1tFwdHR02NdDNE2q5yzO
CzA0ytO0qEZ3Mgjy3EubZlW4jtUxEk/fgSKLYMrg6Fw/jcnJSXsMqwAhmL9DMEN9R+gmUWH+bExc
fGnx/PPPP0WvkzgHu/fv39OoEUzYjMZSU6Lr/UxFRkVTXoBgUmZAMGHDGg5NEcmpwb07dvPmTTtF
u14oXd2Vd3Z2UrmIB2UGBBM2ruGQx59e5dAUkrz4bty4YYVzvdAzHE3t4uyDeFBmQDABwwG0AcoM
CCZgOIA2QJkBwQQMB9AGKDMgmIDhANoAZQYEEzAcQBugzIBgAo0GaAOUGRBMAAwH0AYoMyCYgOEA
2gBlBgQTMBxAG6DMgGAChgNoA5QZEEzAcABtgDIDggkYDqANUGZAMAHDAf+nvfuLsHLf/wB+sW3J
SA7JlmQbkiRjDMmWbYzoYtu6ODZHFzlXkeSYi3QzkjFGJEmOREYXGcew5Ui2RJJjdDEkGV0kRpJk
24y5SMb2/fl8t2f9nvW0/jxr/uya3evFsmet5+9a892fd8+zvvP9agPeMwITFA/87r137b75d68l
oHjgd+4zoMbvXCtgRQ3J48t5oN1r9wITXGUA9WuAjwAEJiAwQWACAhMEJiAwQWACAhMEJiAwQWAC
AhMEJiAwAYEJCEwQmIDABIEJCEwQmIDABIEJCEwQmIDABIEJCExAYAICEwQmIDBBYAICEwQmIDBB
YAICEwQmIDBBYAICE/zPIjBBYAICExCYIDABgQkCExCYIDABgQkCExCYIDABgQkCExCYgMAEBCYI
TEBgwjoFZfUBCExAYAICE1YfmoDABAQmIDBBYAICEwQmIDDhcwlNQGACAhMQmKx1cHh8OQ9AYOIq
C79zEJgonPjdg8BEwUQbAIGJYok2AAITxRJtAAQmiiXaAAhMFEu0ARCYoFiiDYDAZEMUy2fPnvmg
BSYITP7axfL9+/dp9+7dqzrGpk2bPllRX6swWO1+PvX2AhMEJutYLJeXl9Pf//73z6LYf+qiLjBB
YCIw2y4bHh5Or169qlVQ7969m77++uv01Vdfpf3796eHDx829l8dv7TV/sqv/f777+nUqVNpy5Yt
aceOHWl6ejovf/HiRRoYGGgZ7Dt37kxLS0sd9xs/T01NpV27duXzjPP95ZdfGss/fPiQjh8/njZv
3pz27NmTZmdn2+5nJedfNj4+nrZu3Zr6+vrS6Oho07I62wtMEJh8RoF5//792gW1HD737t1L/f39
bY/RLXAuX76cJicnc3C8e/cuHTp0qLF8ZGSkEcaFCMETJ050fX/x848//phev36dn8f5xnkXzp07
l2ZmZvLPd+7cSXv37l1RYHY6/3Dt2rV8zrE8wj4C8cKFC7W3F5ggMPnMArOXdbZv394Im27bdwuc
oaGhfLVXmJubayyPIDty5EjTtrH+kydPagVmEZatlkdARkjV2c9Kzz8MDg5+dJzyPzC6bS8wQWCy
gQMzripjvQiD8+fPryowy1d9IcKlvDxuqT5//rwRJhEwdc691+Ou1X6q5x/Lq7eq4xZx3e0FJghM
NnBghsePHzeuAM+cObNmgVldPjExkU6ePJl/ju8cr1+//lkHZnV5ORxb6ba9wASByQYPzMLTp087
Bkz1+cLCQtNrBw8ebLolOT8/37Q8vteLjjlv377NHWfiT1/WIujiz2dWcku21/OPTlGLi4ttz7nb
9gITBCYbODDj+7/oKRuqnWki3OK7wyIEyh2EohdudMQpH+PWrVv5KrLo9BIdfarnEFeWR48eTadP
n6597t0CMzr9xK3l8ODBg7adflZ7/pcuXWp06olHPI8eyb28f4EJApMNGphxO3bfvn2NP9cowjNE
D9AYvKAYwKAI1Fg3rupi3eoxLl68mLZt25avIKNXaXV5/MlHvNZtFKFeAjOuVH/66ad8bvFe4vvR
VuutxfmPjY3lPxuJzyQC982bNz1tLzBBYPIZBubnKAImOv8gMEFgoli2Ebcq4wqt2hsXgQkCE8Wy
JL4TPXz4cMfOPghMEJgolmgDIDBRLNEGQGCiWKINgMBEsUQbAIGJYok2AAITxfKvodsgBqtdXxsA
gYliuaGKaLvRe4qRhOqqrv+lBofARGDCX7RYrlXICwqfAwhM1jR84uepqak8FF0xVmwx+Hg7Z8+e
zWOlxsTSN2/e7GlM15cvX+bxVWOAgjjWnj170u3btzteYVbnl+y2n1brx3+XlpbSzp07PxoUIQaO
j1lGCuPj43mc176+vjQ6OiowQWAiMP/4OYInZhwJ1dlIqi5fvtyYbSPGfI0JnnsJzIGBgTxjRzGb
x9WrV3PwdgrMVvvtZT/l5zHXZswgUn1PEZIhBkOPf0DEPpeXl9P09HQeYF5ggsBEYDbCsk6RHRwc
bLpCK2YWqRuYrZQnXa4bmL3sp/z8+fPn+SqzmBsz/vvtt982PoN4f9V5M/v7+wUmCEwEZm8BV736
jHDpdX8xXVjMT3ns2LE81VadkGy137r7qT7//vvv81VkiKvUuMIuv7/qLd1yEAtMEJgIzBUFZq/7
i+88Y/LmGzdupPv37+fbuisJzF72U31+586d/J1niO8uY/tWV6l/5TYAAhPWOTC/++679NtvvzWe
z8/Pd9zfwsJC02vRWWhxcbHt8rqB2ct+Wj2PTk7x3WXcji2LAC3vV2CCwERgrigwf/7559xLNm7F
vnv3Lo2MjDStX+5l++rVq3y7s7w8gqrozRphe+DAgVohGb1h43vG6NFaZz/V9avvKTry7Nix46MO
PdEhaHJystGZKJ4PDw8LTBCYCMzeO+lET9LokfrNN9/k0CqvX/SyjVubu3fvTnfv3m1a/ujRo9yJ
JtaJW6ozMzO1AjOCLQYjKAYk6Laf6vrV9/Trr7/mZRH6VTGBdVzBxvII/LjdKzBBYPIFBqairA2A
wASBid8NCEw+z2LZ6zivCEwQmCiWaAMgMFEs0QZAYKJYog2AwESxRBsAgQmKJdoACEw2TrF89uyZ
D11ggsBEseym+ucl63l8QeBzAoHJhi2W3QY8R2CCwGRDFcsY37UY7zVm53j48GF68eJFGhgY+Gjd
5eXlPOHy0tJS3l/MIxkDn8e25YHWq3NIFq9duXKl5fqF8fHxtHXr1tTX15dGR0e7nmer99ZpPW1A
uUBgwoqLZTm47t27lwcxDzHzSDVsIiBPnDjR2F8MRh6zgIRioPVOV5g//PBD2/VjEPfYf8wKEsE8
PT3dNHtIu/OsHqvTetqAcoHAhBUXy5hpJGb3qIqJlY8cOdL02tDQUHry5Eljf0X4tTpGq8DstP7g
4GAOy7Jy2LU7z+p+Oq2nDSgXCExYcbGMq7BYFoF1/vz5pmVx+/T58+f557m5uRyYnfbXy6TNra4M
q7dy47ZqnfMs76fTetqAcoHAhFUVy8ePHzeuKM+cOdN4fWJiIp08eTL/fPz48XT9+vV1C8xyOPZ6
ntV9t1tPG1AuEJiwJsXy6dOnTevFhMqbN29Ob9++zZ1x3r9/v26BGR10FhcXa72X6nm2e2/V9bQB
nwUCE1ZcLPfu3Zt7loZqR5ziyvLo0aPp9OnTPQVgBG18Z/nhw4da61+6dClNTk7m7zHjEc+Hh4dr
nWd5P93ejzYAAhNWVCzj9uW+ffsaf+pRhE1hdnY2b1sduadbAEYP1xi8oBjAoNv6YWxsLG3ZsiVv
Ez1w37x5U+s8y/vp9n60ARCYsC7FMkIrOv8gMEFgoli2EbdG46pPb1OBCQITxbKD+B7y8OHDTZ19
EJggMFEs0QZAYKJYairagDaAwATFEm0ABCaKJdoACEwUS7QBEJgolmgDIDBRLNEGQGCiWKINgMBE
sUQbAIEJiiXaAAhMFEu0ARCYKJZoAyAwUSzRBkBgomDidw8CE4UTv3MQmHyZBdTjy3kAAhNcaQEC
EwQmIDBBYAICEwQmIDBBYAICEwQmIDBBYPoQQGACAhMQmCAwAYEJAhMQmCAwAYEJAhMQmCAwAYEJ
AhMQmIDABAQmCExAYILABAQmCExAYILABAQmCExAYILABAQmIDABgQkCExCYIDABgQkCExCYIDAB
gQkCExCYIDABgQkCExCYgMAEBCYITEBggsAEBCZ88qCsPgCBCQhMQGDC6kMTEJiAwAQEJghMQGCC
wAQEJnwuoQkITEBgAgKTtQ4Ojy/nAQhMXGXhdw4CE4UTv3sQmCiYaAMgMFEs0QZAYKJYog2AwESx
RBsAgYliiTYAAhMUS7QBEJj8ZYrls2fP/DIEJghMNl6xjNenp6f/tOK6adOmNX0vQkBggsDkTwvM
oaGh9P79+z+luK7FfhV+nxsITD5JYF6/fj2dP3++4/pnz55NfX19afPmzWl4eDi9fv267bHu3r2b
vv766/TVV1+l/fv3p4cPHzb2WR3jtNV5lV/7/fff06lTp9KWLVvSjh078tVwpyvM8fHxtHXr1nyu
o6Ojtc5LYILAhFqBGQ4cONAUguX1L126lK5evZrDKx7Xrl1Lx48fb3usCKVffvkl/3zv3r3U39/f
9jy6Bebly5fT5ORkPu67d+/SoUOH2gZmnNfU1FRed3l5OYfrhQsXap2XwASBCbUC89GjR+kf//hH
y/X37duXPnz40HgeP2/btq3tsbZv355mZmZqnUe3wIzbxeVjz83NtQ3MwcHBHJZl5VDsdF4CEwQm
1ArMEIEZwVl9PW5htrqKbCeu3mL7CLBut3q7BWb1OBGI7QIz1q3e9i2fe6fzEpggMKF2YL569Srf
mu0WWnWK7+PHj9OdO3fSkSNH0pkzZ9YsMKvLuwV73fMSmCAwoXZghrjyik5A5dejg0z1lmzdPw95
+vRpx0461ecLCwtNrx08eLDp2PPz8233F+e5uLi4ovMSmCAwoafAjD8viVuW1U4/V65caXT6+fe/
/512797d9lh79+7NPVJDdLIpXyVGL9voXFSEYLkjTlzh/vjjj03HvnXrVpqYmGh0+hkZGWkbmHGe
RQeheMTz6NFb57wEJghM6CkwQ/VPN0LxZyXxiB6yL168aHusuO0ZHYXiFmmEUhFSIXqtxtVpcYVa
BFesGyEc61aPffHixdzJKP5cJHrCdrpiHRsby3+CEvuP8H3z5k2t8xKYIDBBsUQbAIGJYok2AAIT
xRJtAAQmiiXaAAhMFEu0ARCYKJZoAyAwUSzRBkBgoliiDYDABMUSbQAEJutTLNeqiK52P+u5vaDw
OYDA5LMplp9zYOIzAoHJml5hxs9TU1Np165djfFWi4HRQwyYHuPIxgDqe/bsSbOzs2330+k4MTD6
qVOn8pivO3bsaDl27fj4eB47NsauHR0dbVpWZ/uVvkeBCQITgVkrTGLA8phNJFRn9Dh37lyamZnJ
P8eckjH7x0oC8/Lly41ZRWIGkkOHDjUtjwHWI9Ri+fLycg7EGLS97vareY8CEwQmArNWmBRB0mp5
BGSEVJ39dFo+NDTUNMfl3Nxc0/KYXqx6nP7+/trbr+Y9CkwQmAjMVQddpyux1ewnwrG6PJ6XH3H7
tO72qzk3gQkCE4H52QZmdXk5HFvptr3AFJggMPmkgRkTPK/kluzCwkLTawcPHmy6pTo/P9+0fP/+
/WlxcbHte+m2vcAUmCAw+aSBGZ1+7t27l39+8OBB204/5Z6nr169yp1systv3bqVJiYmGp12RkZG
mpZfunSp0aknHvF8eHi49vYCU2CCwOSTBub79+/TTz/9lANx3759ubNNq/WKnqdxazWuSu/evfvR
vi9evJi2bduW/3QkesVWl4+NjeU/G9m0aVMO3Ddv3vS0vcAUmCAwUSzRBkBgoliiDYDARLFEGwCB
iWKJNgACE8USbQAEJool2gAITFAs0QZAYKJYog2AwOQLKJbPnj1b0bK1WF8bAIEJG6ZYxkg+7c6z
umw1+8LnAf4PYEMXy7pD2gkEgQkCk09eLM+ePZvHbd2+fXu6efNmT2Ovvnz5Mo/1unnz5jx+7J49
e9Lt27eb1p2amkq7du3KY8uWB2avznlZ3nerZZ2O1W5fS0tLaefOnXkc3LKY7SRmRSmMj4/ncWn7
+vrS6OiowASBicBsdvny5cbMHzHA+dDQUE+BOTAwkGcPKWYWuXr1ag7e8roRcq9fv87Pi4HZ2+2/
07HrHKvVvk6ePJlnPKm+7wjJEIO3R6jHPpeXl9P09HS6cOGCwASBicD8f4ODg01XX7Ozs6ue3aM8
AXSsW4RlnVDsduxux2q1r+fPn+erzGIuz/jvt99+2ziv+Ayq83z29/cLTBCYCMz/V77aK8Kk18B8
/Phxnivz2LFjedqvXrbvNTB7OVb5+ffff5+vIkNcpcZVb/kzqN7SLQexwASBicD8KDDrhFb5tfjO
MyaSvnHjRrp//36+rbtegdnrscrP79y5k7/zDPHdZWzf6ir1S2wDIDChRrH87rvv0m+//dZ4Pj8/
3zGEFhYWml6LzkKLi4ttl69lYPZ6rOrz6HgU313G7diyCNDyfgUmCEwE5kd+/vnn3Es2bsW+e/cu
jYyMNK1b7tX66tWrfCuzvDxCqOipGmF74MCBngIzerzGd4nRa7Xbsm7H6rSvEB15duzY8VGHnugQ
NDk52ehMFM+Hh4cFJghMBGaz6CUavU2/+eabHEjldYterXHbcvfu3enu3btNyx89epQ7yMQ6cbt0
Zmamp8CM8IoBB4pBBzot63asTvsKv/76a14W/zCoGhsby1ewsTz+URC3ewUmCEwEpsKqDYDABIGJ
3ysITP6EYtnrGK4ITBCYKJZoAyAwUSzRBkBggmKJNgACE8USbQAEJool2gAITL6MYvns2TMfusAE
gYli2U31T1PW8/iCwOcEApMNWyy7DYSOwASByYYqljE2bDFWbMza8fDhw/TixYs0MDDw0brLy8t5
IualpaW8v5hfMgZEj23Lg7RX55YsXrty5UrL9Qvj4+Np69atqa+vL42OjnY9z1bvrdN62oBygcCE
FRfLcnDdu3cvD24eYtaSathEQJ44caKxvxikPGYHCcUg7Z2uMH/44Ye268cA8LH/mC0kgnl6erpp
VpF251k9Vqf1tAHlAoEJKy6WMUtJzPpRFRMuHzlypOm1oaGh9OTJk8b+ivBrdYxWgdlp/cHBwRyW
ZeWwa3ee1f10Wk8bUC4QmLDiYhlXYbEsAuv8+fNNy+L26fPnz/PPc3NzOTA77a+XyZxbXRlWb+XG
bdU651neT6f1tAHlAoEJqyqWjx8/blxRnjlzpvH6xMREOnnyZP75+PHj6fr16+sWmOVw7PU8q/tu
t542oFwgMGFNiuXTp0+b1ouJljdv3pzevn2bO+O8f/9+3QIzOugsLi7Wei/V82z33qrraQM+CwQm
rLhY7t27N/csDdWOOMWV5dGjR9Pp06d7CsAI2vjO8sOHD7XWv3TpUpqcnMzfY8Yjng8PD9c6z/J+
ur0fbQAEJqyoWMbty3379jX+1KMIm8Ls7GzetjpyT7cAjB6uMXhBMYBBt/XD2NhY2rJlS94meuC+
efOm1nmW99Pt/WgDIDBhXYplhFZ0/kFggsBEsWwjbo3GVZ/epgITBCaKZQfxPeThw4ebOvsgMEFg
oliiDYDARLHUVLQBbQCBCYol2gAITBRLtAEQmCiWaAMgMFEsqwMeIDBBYLJhi2XM8BFzVa6HYqSf
v3qQ1N1HjGD04MEDgQkCk40YCjEVVjGN15dYpP/Mc4zPuTxNmsAEgckGCYX//e9/eXCC6ro3btxI
27ZtS3/729/Sf/7znzwYeozzGuOzxqDmZePj43k2k76+vjQ6Otq0n/IjvHz5Ml9lxaAIsa89e/ak
27dvdzz3btvEvqempvIQfsUYsuVzrLP9ixcv0sDAwEfHXl5eTjt37kxLS0t5XNrYPo4Rs6s8fPiw
5efbab0Qn3d87gITBCYbKDD/9a9/pZs3b3607j//+c8cFv/9739zUJ44cSI/r84Acu3atRxWMYxe
LJ+ens4Dr7c7boTSrVu3GrOSXL16NW3fvr3juXfbJo4RgRizo4TqOdbZPoyMjHwUbvHe4r2HchDH
bez+/v6W77PTeiH+MRKfu8AEgckGCswDBw6k+fn5j9Ytwqd4Xp6rsryvuJ0bIVTWLkjaqTN5dKdt
qudb57jV7UMx6XRZ3D598uRJ/jlCdmZmpuvn22m9EJ93fO4CEwQmGygw4zZlNfC6Tf5cvZqq3npt
FUZlMQXXuXPn0rFjx/JUXHUKeadt6kwdVnf7uK1bfJ87NzfX9H1jXC3GuvGPhOqA9OV9dFovxOcd
t68FJghMNlBgtrq66yUwu10dVreN278xyXPclrx//36ePqxYp9V3nt22qROYvWw/MTGRTp48mX+O
ybOvX7/+UfAWV6JnzpzpGNCt1iv/Q0NggsDkC7rCjE4t5du13Y4b34eW119YWOhayLtt0y0we9n+
3bt3+TN5+/Zt7sjUbqaWp0+fdj2HVuuF+K7XFSYITDZYYMZ3aXHrcaWBGb1nJycnGx1q4vnw8HBT
IMf3ix8+fMjP45Zn0UO1+C6vWyHvtk23wOx1+7iyPHr0aDp9+nTT63GVGj1gQ7VjUXkfndYL8Z2o
7zBBYLLBAjN6a0ZP15UGZohJpuMqLgYpiN6qccuzED1m4/ViAINHjx7lTkERIhEs0TmmWyHvtk23
wOx1+9nZ2fxadZSiuM0a338Wf7pShGJ1H53WC3GbVy9ZEJhssMCMcChfEZJy4MdV6Xo5dOhQDlWB
CQKTDRSYIXpzGvP1D3FbOa6YW/VuXQtxSzg+78+tDYDAhBrFMr5ni+/s+OM71xiJp11nn9WKz9lY
siAw2aCBiTYAAhMUS7QBEJgolmgDIDBRLNEGQGCiWKINgMBEsUQbAIGJYok2AAITxRJtAAQmiiXa
AAhMUCzRBkBgoliiDYDARLFEGwCBiWKJNgACEwUTv3sQmCic+J2DwOQLL6AeX84D+MP/AXfdVE7v
g5RYAAAAAElFTkSuQmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-03-07 05:33:21 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUUAAAFzCAIAAAAmNYy6AAAQTklEQVR42u3dvW4kVRPG8ZGQEIED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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-07-18 12:26:27 +0100" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Thrombosis, outcome: 1.1 Symptomatic thrombosis.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAmkAAABgCAMAAABxPxUBAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-07-18 12:26:40 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.02" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Thrombosis, outcome: 1.2 Asymptomatic thrombosis.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAmkAAABgCAMAAABxPxUBAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2013-07-18 12:26:55 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-002.01" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Bleeding events, outcome: 2.1 Major bleeding.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAmkAAABgCAMAAABxPxUBAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2013-07-18 12:27:10 +0100" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-002.02" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Bleeding events, outcome: 2.2 Minor bleeding.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAmkAAABgCAMAAABxPxUBAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2011-09-06 07:44:26 +0100" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2011-09-06 07:44:26 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-02-14 11:58:05 +0000" MODIFIED_BY="Marlene Stewart">Anticoagulant feedback</TITLE>
<DATE_SUBMITTED>
<DATE DAY="14" MONTH="2" YEAR="2011"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2011-09-06 07:44:26 +0100" MODIFIED_BY="[Empty name]">
<P>Feedback received on this protocol, and other reviews and protocols on anticoagulants, is available on the Cochrane Editorial Unit Website at <A HREF="http://www.editorial-unit.cochrane.org/anticoagulants-feedback">http://www.editorial-unit.cochrane.org/anticoagulants-feedback</A>.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY/>
<FEEDBACK_CONTRIBUTORS/>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2013-08-02 10:39:16 +0100" MODIFIED_BY="Karen Welch">
<APPENDIX ID="APP-01" MODIFIED="2013-08-02 09:48:07 +0100" MODIFIED_BY="Karen Welch" NO="1">
<TITLE MODIFIED="2013-06-11 08:40:44 +0100" MODIFIED_BY="Karen Welch">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-06-11 09:13:41 +0100" MODIFIED_BY="Karen Welch">
<TABLE COLS="3" ROWS="27">
<TR>
<TD ALIGN="RIGHT">
<P>1</P>
</TD>
<TD>
<P>MeSH descriptor: [Catheterization, Central Venous] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>711</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>MeSH descriptor: [Catheters] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>966</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>broviac </P>
</TD>
<TD ALIGN="RIGHT">
<P>26</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>port near/3 cath </P>
</TD>
<TD ALIGN="RIGHT">
<P>42</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>portacath </P>
</TD>
<TD ALIGN="RIGHT">
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>hickman </P>
</TD>
<TD ALIGN="RIGHT">
<P>179</P>
</TD>
</TR>
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P>catheter* </P>
</TD>
<TD ALIGN="RIGHT">
<P>12832</P>
</TD>
</TR>
<TR>
<TD>
<P>#8</P>
</TD>
<TD>
<P>TCVC or PICC or CVC or CVAD </P>
</TD>
<TD ALIGN="RIGHT">
<P>322</P>
</TD>
</TR>
<TR>
<TD>
<P>#9</P>
</TD>
<TD>
<P>venous near/3 (line or device) </P>
</TD>
<TD ALIGN="RIGHT">
<P>289</P>
</TD>
</TR>
<TR>
<TD>
<P>#10</P>
</TD>
<TD>
<P>cannula* </P>
</TD>
<TD ALIGN="RIGHT">
<P>1653</P>
</TD>
</TR>
<TR>
<TD>
<P>#11</P>
</TD>
<TD>
<P>#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 </P>
</TD>
<TD ALIGN="RIGHT">
<P>14107</P>
</TD>
</TR>
<TR>
<TD>
<P>#12</P>
</TD>
<TD>
<P>MeSH descriptor: [Thrombosis] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>4753</P>
</TD>
</TR>
<TR>
<TD>
<P>#13</P>
</TD>
<TD>
<P>thrombo* or clot* </P>
</TD>
<TD ALIGN="RIGHT">
<P>25385</P>
</TD>
</TR>
<TR>
<TD>
<P>#14</P>
</TD>
<TD>
<P>#12 or #13 </P>
</TD>
<TD ALIGN="RIGHT">
<P>25594</P>
</TD>
</TR>
<TR>
<TD>
<P>#15</P>
</TD>
<TD>
<P>#11 and #14 </P>
</TD>
<TD ALIGN="RIGHT">
<P>1637</P>
</TD>
</TR>
<TR>
<TD>
<P>#16</P>
</TD>
<TD>
<P>MeSH descriptor: [Heparin, Low-Molecular-Weight] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>1632</P>
</TD>
</TR>
<TR>
<TD>
<P>#17</P>
</TD>
<TD>
<P>*heparin* or LMWH or nadroparin* or fraxiparin* or enoxaparin or Clexane or klexane or lovenox or dalteparin or Fragmin or ardeparin or normiflo or tinzaparin or logiparin or Innohep or certoparin or sandoparin or reviparin or clivarin* or danaproid or danaparoid or bemiparin or bioparin or Alphaparin or Troparin </P>
</TD>
<TD ALIGN="RIGHT">
<P>8499</P>
</TD>
</TR>
<TR>
<TD>
<P>#18</P>
</TD>
<TD>
<P>antixarin or ardeparin* or bemiparin* or Zibor or cy 222 or embolex or monoembolex or Mono-embolex or parnaparin* or "rd 11885" or tedelparin or Kabi-2165 or Kabi 2165 </P>
</TD>
<TD ALIGN="RIGHT">
<P>196</P>
</TD>
</TR>
<TR>
<TD>
<P>#19</P>
</TD>
<TD>
<P>emt-966 or emt-967 or pk-10169 or pk10169 </P>
</TD>
<TD ALIGN="RIGHT">
<P>20</P>
</TD>
</TR>
<TR>
<TD>
<P>#20</P>
</TD>
<TD>
<P>cy-216 or cy216 or seleparin* or tedegliparin or seleparin* or tedegliparin* or tedelparin or Boxol or Liquemine </P>
</TD>
<TD ALIGN="RIGHT">
<P>85</P>
</TD>
</TR>
<TR>
<TD>
<P>#21</P>
</TD>
<TD>
<P>fr-860 </P>
</TD>
<TD ALIGN="RIGHT">
<P>14</P>
</TD>
</TR>
<TR>
<TD>
<P>#22</P>
</TD>
<TD>
<P>wy90493 or wy-90493 </P>
</TD>
<TD ALIGN="RIGHT">
<P>10</P>
</TD>
</TR>
<TR>
<TD>
<P>#23</P>
</TD>
<TD>
<P>kb-101 or kb101 or lomoparan or orgaran </P>
</TD>
<TD ALIGN="RIGHT">
<P>65</P>
</TD>
</TR>
<TR>
<TD>
<P>#24</P>
</TD>
<TD>
<P>parnaparin or fluxum or lohepa or lowhepa or "op 2123" or parvoparin </P>
</TD>
<TD ALIGN="RIGHT">
<P>52</P>
</TD>
</TR>
<TR>
<TD>
<P>#25</P>
</TD>
<TD>
<P>AVE5026 or M118 or RO-14 </P>
</TD>
<TD ALIGN="RIGHT">
<P>44</P>
</TD>
</TR>
<TR>
<TD>
<P>#26</P>
</TD>
<TD>
<P>#16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 </P>
</TD>
<TD ALIGN="RIGHT">
<P>8566</P>
</TD>
</TR>
<TR>
<TD>
<P>#27</P>
</TD>
<TD>
<P>#15 and #26 in Trials</P>
</TD>
<TD ALIGN="RIGHT">
<P>335</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-08-02 10:39:16 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2013-08-02 10:39:16 +0100" MODIFIED_BY="[Empty name]">Authors' MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-07-12 23:57:42 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="4" ROWS="5">
<TR>
<TD VALIGN="TOP">
<P>Set</P>
</TD>
<TD VALIGN="TOP">
<P>History</P>
</TD>
<TD VALIGN="TOP">
<P>Results</P>
</TD>
<TD VALIGN="TOP">
<P>Comments</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>catheters/ or catheters, indwelling/ or catheterization/ or catheterization, central venous/ or heart catheterization/ or catheterization, swan-ganz/</P>
</TD>
<TD VALIGN="TOP">
<P>108618</P>
</TD>
<TD VALIGN="TOP">
<P>Catheter Terms</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>exp Heparin, Low-Molecular-Weight/</P>
</TD>
<TD VALIGN="TOP">
<P>9890</P>
</TD>
<TD VALIGN="TOP">
<P>Heparin Terms</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>exp Thrombosis/ or prophyla*.mp.</P>
</TD>
<TD VALIGN="TOP">
<P>254495</P>
</TD>
<TD VALIGN="TOP">
<P>Outcome Terms</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>1 and 2 and 3</P>
</TD>
<TD VALIGN="TOP">
<P>125</P>
</TD>
<TD VALIGN="TOP">
<P>FINAL Results</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2013-08-02 10:39:12 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2013-08-02 10:39:12 +0100" MODIFIED_BY="[Empty name]">Authors' EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-07-13 00:07:25 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="4" ROWS="5">
<TR>
<TD VALIGN="TOP">
<P>Set</P>
</TD>
<TD VALIGN="TOP">
<P>History</P>
</TD>
<TD VALIGN="TOP">
<P>Results</P>
</TD>
<TD VALIGN="TOP">
<P>Comments</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>catheter/ or "catheters and tubes"/ or exp central venous catheter/ or indwelling catheter/ or intravenous catheter/ or subclavian vein catheter/ or umbilical artery catheter/ or Swan Ganz catheter/ or blood vessel catheterization/ or catheterization/ or exp artery catheterization/ or exp vein catheterization/</P>
</TD>
<TD VALIGN="TOP">
<P>98873</P>
</TD>
<TD VALIGN="TOP">
<P>Catheter Terms</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>exp low molecular weight heparin/</P>
</TD>
<TD VALIGN="TOP">
<P>38879</P>
</TD>
<TD VALIGN="TOP">
<P>Heparin Terms</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>thromboembolism/ or exp embolism/ or exp thrombosis/ or exp venous thromboembolism/ or prophylaxis/ or embolism prevention/ or thrombosis prevention/ or prophyla*.mp.</P>
</TD>
<TD VALIGN="TOP">
<P>484432</P>
</TD>
<TD VALIGN="TOP">
<P>Outcome Terms</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>1 and 2 and 3</P>
</TD>
<TD VALIGN="TOP">
<P>979</P>
</TD>
<TD VALIGN="TOP">
<P>FINAL Results</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;No studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1 study included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;21 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1400 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1400 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;335 records identified from CENTRAL search&lt;/p&gt;&lt;p&gt;125 records identified from MEDLINE search&lt;/p&gt;&lt;p&gt;979 records identified from EMBASE search&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="171"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;39 records identified form Specialised Register&lt;/p&gt;&lt;p&gt;9 additional records identified through review of references&lt;/p&gt;" WIDTH="200"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1379 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;16 full-text articles excluded:&lt;/p&gt;&lt;p&gt;7 adult patients only&lt;/p&gt;&lt;p&gt;3 prospective cohort studies&lt;/p&gt;&lt;p&gt;5 retrospective cohort studies&lt;/p&gt;&lt;p&gt;1 mixed design&lt;/p&gt;&lt;p&gt;4 full-text articles deemed not relevant:&lt;/p&gt;&lt;p&gt;3 editorials&lt;/p&gt;&lt;p&gt;1 review&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>